Page last updated: 2024-08-23

paclitaxel and Cancer of Head

paclitaxel has been researched along with Cancer of Head in 457 studies

Research

Studies (457)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	114 (24.95)	18.2507
2000's	184 (40.26)	29.6817
2010's	121 (26.48)	24.3611
2020's	38 (8.32)	2.80

Authors

Authors	Studies
Brett, ML; Colley, HE; Coole, SF; Danson, SJ; Dossetter, AG; Griffen, EJ; Harrison, J; Jackson, LV; Jennings, LR; Lockey, PM; Mason, DP; Muthana, M; Norman, D; Thompson, MJ; Tulasi, V; Williams, L; Wong, M	1
Agostini, M; Almeida, LY; Bastos, DC; Coletta, RD; Cuadra Zelaya, FJM; Daher, URN; Graner, E; Kowalski, LP; Mariano, FS; Moreira, FDS; Ortiz, CA; Santos, GASD	1
Atkinson, V; Avsar, E; Baldini, C; Callies, S; Carpentier, AF; Cervantes, A; Cosman, R; Estrem, ST; Gandhi, L; Kondo, S; Le Rhun, E; Löhr, M; Man, M; Mason, W; Melisi, D; Ochsenreither, S; Redman, R; Sepúlveda-Sánchez, JM; Simonelli, M; van der Westhuizen, A; Vieito, M; Warren, L; Yap, TA; Zhao, Y	1
Alonso-Ovies, A; Cabezas-Camarero, S; Cabrera-Martín, MN; Merino-Menéndez, S; Pérez-Segura, P; Plaza-Hernández, JC	1
Aytatli, A; Barlak, N; Caglar, HO; Gundogdu, B; Ittmann, M; Karatas, OF; Sanli, F; Tatar, A	1
Chera, B; Deal, AM; Gilbert, J; Hackman, T; Hayes, DN; Liao, JJ; Miller, K; Murphy, B; Olson, JG; Sheth, S; Weiss, J; Weissler, M; Woods, J	1
Di Fabio, F; Filippini, DM; Mosca, M; Rihawi, K; Rojas, FL; Tober, N	1
Fang, J; Feng, L; Huang, T; Wang, L; Wang, R; Yang, Y	1
Bhatia, AK; Burtness, B; Deshpande, H; Forman, R	1
Alamgeer, M; Coleman, A; Giddings, C; McDowell, L; Safdar, A; Sigston, E; Subramaniam, A; Wang, Y	1
Hara, H; Hashimoto, K; Jiromaru, R; Komune, N; Kuratomi, Y; Manako, T; Masuda, M; Matsuo, M; Nakagawa, T; Nishimura, E; Takeuchi, T; Toh, S; Wakasaki, T; Yamauchi, M; Yasumatsu, R	1
Bodiwala, K; Khadela, A; Mansuri, M; Sureja, D; Vyas, B	1
Chang, X; Chen, L; Chen, X; Gao, J; Gooding, JJ; Mu, W; Sun, S; Tian, R; Wu, Q; Wu, Y; Yang, G	1
Becker, JN; Bruns, F; Christiansen, H; Hermann, R; Sonnhoff, M; Wichmann, J	1
Givi, B; Kim, S; Samant, S; Talwar, A; Tozan, Y; Yu, S	1
Ding, J; Fan, G; Tan, S; Tu, Y; Wu, N; Xiao, H; Zhang, J; Zhang, W; Zou, C; Zou, WQ	1
Bajbouj, K; Haider, M; Hamda, M; Jagal, J; Okendo, J; Sahnoon, L; Semreen, MH; Sharaf, BM; Soares, NC	1
Chen, Y; Dong, M; Dou, S; Huang, Y; Ju, W; Li, J; Liu, Y; Shi, W; Sun, J; Sun, Q; Tang, Y; Zhang, D; Zhao, T; Zhong, L; Zhou, X; Zhou, Z; Zhu, D; Zhu, G; Zhu, Q	1
Chen, L; Gelblum, D; Han, J; Hesse, J; Kang, JJ; Lee, NY; McBride, SM; Michel, L; Raab, G; Riaz, N; Shamseddine, A; Sherman, EJ; Tsai, CJ; Wong, RJ; Yu, Y; Zakeri, K	1
Kohn, N; Locke, M; Seetharamu, N	1
Cao, F; Fang, Q; Liu, X; Wu, D; Xu, P	1
Enokida, T; Fujisawa, T; Hoshi, Y; Ishii, G; Okano, S; Onaga, R; Sakashita, S; Sato, M; Tahara, M; Takeshita, N; Tanaka, H; Tanaka, N; Wada, A	1
Carvalho, AL; Iyer, NG; Leong, HS; Lim, SK; Melendez, ME; Ramos, CRN; Rodrigues-Junior, DM; Tan, DSW; Tan, SS; Vettore, AL; Viana, LS	1
Andrade, ES; Arantes, LMRB; Carvalho, AL; de Carvalho, AC; de Castro, G; De Marchi, P; de Souza Viana, L; Evangelista, AF; Kuhlmann, PA; Laus, AC; Melendez, ME; Reis, RM	1
Adkins, DR; Daly, M; Gay, HA; Jackson, R; Johnson, KCC; Ley, J; Lu, J; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Zevallos, J	1
Herrmann, R; Holzgrabe, U; Polednik, C; Roller, J; Schmidt, M; Skaf, J	1
André, F; Frischhut, N; Nguyen, VA; Schmuth, M; Skvortsov, S; Walder, A	1
Hamauchi, S; Kawakami, T; Mori, K; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Shirasu, H; Yokota, T	1
Doi, K; Fumita, S; Haratani, K; Hayashi, H; Ishikawa, K; Iwasa, T; Kanemura, H; Kitano, M; Kurosaki, T; Mitani, S; Nakagawa, K; Nishimura, Y; Otsuki, N; Suzuki, S; Tanaka, K; Yoshida, T	1
Bruera, E; Cohen, L; Ferrarotto, R; Fuller, CD; Guo, M; Hanna, EY; Liu, W; Lopez, G; Meyer, LA; Narayanan, S; Qdaisat, A; Yeung, SJ	1
Pradhan, GS; Rathi, AK; Singh, K; Sunku, R	1
Cabezas-Camarero, S; Cabrera-Martin, MN; Perez-Segura, P; Saiz-Pardo Sanz, M	1
Nagasaka, M; Nguyen, A	1
Adkins, D; Atiq, O; Gitau, M; Ley, J; Liu, J; Oppelt, P; Palka, K; Powell, S; Rigden, C; Spanos, WC	1
Adkins, D; Daly, M; Gay, H; Gitau, M; Jackson, RS; Ley, J; Liu, J; Neupane, P; Oppelt, P; Palka, K; Paniello, R; Pipkorn, P; Powell, S; Rich, J; Spanos, WC; Thorstad, W; Zevallos, J	1
Beppu, S; Hanai, N; Kadowaki, S; Motai, R; Nishikawa, D; Sasaki, E; Sawabe, M; Suzuki, H; Terada, H	1
Adansa, JC; Caballero, J; Cirauqui Cirauqui, B; Iglesias Docampo, L; Lambea Sorrosal, J; Lozano Borbalas, A; Marruecos Querol, J; Martínez-Trufero, J; Mesía Nin, R; Ortega Izquierdo, E; Pajares Bernad, I; Plana Serrahima, M; Planas Toledano, I; Ponce Ortega, JM; Rubió-Casadevall, J; Taberna Sanz, M	1
Bharadwaj, R; Medhi, S	1
Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C	1
Aguilar, MR; Martín-Hita, A; Palao-Suay, R; Riestra-Ayora, J; Sánchez-Rodríguez, C; Sanz-Fernández, R; Yanes-Díaz, J	1
Kii, T; Sakuma, K; Tanaka, A	1
Abemayor, E; Chen, AM; Choi, J; Juarez, JE; St John, M; TenNapel, M	1
Dong, S; Ju, Z; Yang, J	1
Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Nussenbaum, B; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Trinkaus, K; Wildes, TM	1
Baniandrés Rodriguez, O; Ciudad Blanco, C; Ruedas Martínez, A; Vilas Boas, P	1
Fukushima, H; Kawabata, K; Marshall, S; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Taira, S; Takahashi, S; Tomomatsu, J; Yonekawa, H	1
Airoldi, M; Bossi, P; Caldara, A; Caponigro, F; Denaro, N; Ferrari, D; Ferrau, F; Hollander, L; Licitra, L; Lo Vullo, S; Locati, LD; Miceli, R; Moretti, G; Moro, C; Nolè, F; Rinaldi, G; Sponghini, A; Tettamanzi, F; Vaccher, E; Vecchio, S	1
Baxi, SS; Dunn, LA; Fury, MG; Haque, S; Ho, AL; Katabi, N; Korte, S; Pfister, C; Pfister, DG; Sherman, EJ; Xiao, H	1
Carvalho, AL; Cordeiro, FB; da Silva, IDCG; de Souza Viana, L; Laus, AC; Lo Turco, EG	1
Bartscht, T; Hakim, SG; Idel, C; Rades, D	1
Bou-Gharios, G; Hira-Miyazawa, M; Hirai, M; Kawashiri, S; Kitahara, H; Kobayashi, Y; Nakamura, H	1
Hara, H; Hasegawa, Y; Homma, A; Kiyota, N; Minato, K; Muro, K; Onoe, T; Saijo, K; Suzuki, M; Taguchi, J; Tahara, M; Takahashi, S; Ueda, S; Yamanaka, T; Yane, K; Yokota, T	1
Borel, C; Burgy, M; Leblanc, J	1
Hong, JH; Khurelbaatar, T; Lee, JK; Lee, NW; Lee, S; Min, KJ; Ryu, KJ; Song, JY	1
Abdallah, N; Nagasaka, M; Sukari, A	1
Cheng, JD; Chirovsky, D; Lala, M; Mayawala, K	1
Cabezas-Camarero, S; Cabrera-Martín, MN; Pérez-Segura, P	1
Eich, HT; Elsayad, K; Haverkamp, U; Maring, S; Rehkämper, J; Rudack, C; Stenner, M; Wardelmann, E	1
Killock, D	1
Komune, N; Matsuo, M; Nakagawa, T; Taura, M; Uchi, R; Wakasaki, T; Yasumatsu, R	1
Griessmann, M; Landgraf, V; Polednik, C; Roller, J; Schmidt, M	1
Dyckhoff, G; Haefeli, WE; Herold-Mende, C; Reuter, T; Rigalli, JP; Theile, D; Weiss, J	1
Alcaraz, D; Caballero, M; Feliz, L; Grau, JJ; Muñoz-García, C; Pereira, V; Sosa, AE	1
Guntinas-Lichius, O; Hartmann, M; Himmel, M	1
Dellian, M; Dunau, C; Gellrich, D; Jäger, L; Michaelis, U; Strieth, S; Wollenberg, B	1
Barringer, DA; Garden, AS; Holsinger, FC; Hutcheson, KA; Kies, MS; Lewin, JS; Lin, HY; Lisec, A; Papadimitrakopoulou, V; Steinhaus, G; Villalobos, S	1
DeRubeis, MB; Foster, JC; Mason, H; Taylor, JM; Worden, FP	1
Antonuk, AE; Balter, JM; Cornwall, C; Eisbruch, A; Feng, M; Fernandes, LL; Hunter, KU; McShan, D; Schipper, MJ; Vineberg, KA	1
Chen, L; Feldman, LE; Garnett, A; Herman, LC; Smith, B; Spiotto, MT; Weichselbaum, RR	1
Bowlin, GL; Bulysheva, AA; Petrova, SP; Yeudall, WA	1
García-Silva, J; Nespereira-Jato, MV; Peña-Panabad, C; Quindós-Varela, M	1
Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP	1
Dyckhoff, G; Gal, Z; Grabe, N; Herold-Mende, C; Lahrmann, B; Rigalli, JP; Theile, D; Warta, R; Weiss, J	1
Dutta, PR; Fury, MG; Gelblum, DY; Haque, S; Katabi, N; Kurz, S; Lee, JL; Lee, NY; Mueller, B; Ng, KK; Pfister, DG; Rao, SS; Shen, R; Sherman, EJ; Smith-Marrone, S; Wolden, S	1
Armes, SP; Avila-Olias, M; Battaglia, G; Canton, I; Cecchin, D; Colley, HE; Hearnden, V; Hu, K; MacNeil, S; Madsen, J; McKeating, JA; Murdoch, C; Thornhill, MH; Warren, N	1
Deng, W; Guan, Z; Huang, M; Huang, W; Jiang, W; Kang, T; Li, L; Li, S; Liu, Q; Liu, R; Pan, C; Tan, W; Thomas, GR; Wu, J; Ye, W; Ying, X; Zeng, M; Zhang, L	1
Burtness, BA; Forastiere, AA; Kosmidis, EK; Lee, JW; Pectasides, E; Psyrri, A; Rimm, DL; Vassilakopoulou, M; Wanebo, HJ	1
Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K	1
Aoyagi, S; Hata, H; Homma, E; Shimizu, H; Tsujiwaki, M	1
Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E	1
Burtness, BA; Forastiere, AA; Ghebremichael, M; Hancock, MR; Lee, J; Pectasides, E; Psyrri, D; Ridge, JA; Rimm, D; Rosen, FR; Spencer, SA; Tolba, KA; Wanebo, HJ	1
Chen, H; Cheng, L; Huang, JM; Tao, L; Tian, J; Xin, Y; Zhou, L	1
Colbert, PL; Lee, JH; Vermeer, DW; Vermeer, PD; Wieking, BG	1
Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N	1
Arnold, SM; Brill, Y; Dressler, EV; Gleason, JF; Kudrimoti, M; Silver, NL; Valentino, J	1
Andrade Dos Anjos Jacome, A; Arthur Jacinto, A; Boldrini Junior, D; Calheiros Campelo Maia, D; de Aguiar Silva, FC; de Castro Capuzzo, R; de Souza Viana, L; Duarte de Mattos, M; Elias Mamere, A; Lopes Carvalho, A; Roberto Santos, C	1
Bhasker, S; Biswas, A; Gandhi, AK; Mohanti, BK; Raza, MW; Roy, S; Saxena, T; Sharma, A; Thakar, A	1
Maushagen, R; Pries, R; Wollenberg, B	1
Bonerigo, S; Chung, CH; Cmelak, A; Gilbert, J; John, P; Kang, H; Kiess, A; Marur, S; Murphy, BA; Quon, H; Rudek, MA; Tsottles, N; Veasey, A	1
Bisen, PS; Khan, AA; Khan, N; Khan, Z; Prasad, GB; Tiwari, RP	1
Kovács, G; Meyer, JE; Ritter, M; Schröder, U; Teudt, IU; Wollenberg, B	1
Chera, B; Deal, AM; Gilbert, J; Grilley Olson, J; Hayes, DN; Murphy, BA; Weiss, J; Weissler, M	1
Hahlbrock, A; Maushagen, R; Pfannerstill, AC; Pries, R; Rades, D; Rahmanzadeh, R; Reers, S; Stauber, R; Wollenberg, B	1
Borel, C; Ciftci, S; Debry, C; Dupret-Bories, A; Schmaltz, H; Schultz, P; Takeda-Raguin, C	1
Chen, ZG; Majumdar, D; Rahman, MA; Shin, DM	1
Ameri, A; Khoshbakht Ahmadi, H; Mortazavi, N; Novin, K	1
Gill, HS; Mody, MD; Saba, NF	1
Barker, HE; Bhide, S; Harrington, KJ; McLaughlin, M; Newbold, KL; Nutting, CM; Patel, R; Schick, U; Zaidi, S	1
Grauer, D; Henry, D; Kathol, E; Narveson, L; Neupane, P; Rockey, M	1
Han, HY; Jeong, SH; Kim, H; Kim, HJ; Kim, JH; Lee, HE; Ryu, MH	1
Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM	1
Hakim, SG; Rades, D; Schild, SE; Seidl, D; Wollenberg, B	1
Chen, L; Chen, Y; Cheng, B; Tang, Q; Xie, M; Zhao, J; Zhou, X	1
Adansa Klain, JC; Berrocal, A; Caballero Daroqui, J; Cruz-Hernández, JJ; Del Barco Morillo, E; González-Rivas, C; Martínez-Galán, J; Martínez-Trufero, J; Mesía, R; Pastor Borgoñon, M; Vázquez Fernández, S; Vera, R	1
Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS	1
Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM	1
Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S	1
Arndt, CA; Good, AB; Nascimento, A; Welker, KM	1
Argiris, A; Brockstein, BE; Cohen, EE; Haraf, DJ; Kistner, EO; Mittal, BB; Rosen, F; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME	1
Chu, SC; Kao, RH; Li, CC; Wang, TF; Yao, CY	1
Choi, M; Gadgeel, SM; Heilbrun, LK; Jiang, PQ; Smith, DW	1
Bay, JO; Blay, JY; Bompas, E; Brain, EG; Bui, BN; Chevreau, C; Cupissol, D; Fournier, C; Isambert, N; Jimenez, M; Kerbrat, P; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I; Taieb, S	1
Akita, H; Hokari, M; Iwasaki, Y; Kamoshima, Y; Sawamura, Y	1
Bradford, C; Cao, Y; Chepeha, DB; Eisbruch, A; Li, D; Moyer, JS; Mukherji, SK; Popovtzer, A; Prince, ME; Teknos, T; Worden, F	1
Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C	1
Chen, Z; Cho, K; Müller, S; Nie, S; Saba, NF; Shin, DM; Tighiouart, M; Wang, X	1
Becker, JC; Bröcker, EB; Hofmann, UB; Kleine, P; Kneitz, H; Ugurel, S; Wobser, M	1
Clayman, GL; El-Naggar, AK; Henderson, YC; Mazumdar, A; Sen, S	1
Albert, PS; Citrin, D; Colevas, AD; Cooley-Zgela, T; Cotrim, A; Herscher, L; Likhacheva, A; Mansueti, J; Morris, JC; Rudy, SF; Russo, A; Sciuto, L; Smith, S; Solomon, B; Van Waes, C	1
Bier, C; Engels, K; Fetz, V; Habtemichael, N; Knauer, SK; Kovács, AF; Kunkel, M; Mann, W; Schneider, S; Schuon, R; Schweitzer, A; Stauber, RH	1
Hsiao, JR; Huang, BM; Leu, SF	1
Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S	1
Chung, WH; Kim, SS; Kuh, HJ; Rhim, H; Sung, BH	1
Alós, L; Caballero, M; Campayo, M; Grau, JJ; Jansa, S; Monzo, M; Vargas, M	1
Chung, CH; Cmelak, AJ; Diaz, R; Gilbert, J; Jaboin, JJ; Koehler, E; Morales-Paliza, M; Murphy, BA; Murphy, PB; Phillips, JG; Shyr, Y; Stinson, S; Yarbrough, WG	1
Corry, P; Moros, EG; Peñagarícano, JA; Ratanatharathorn, V; Yan, Y	1
Allen, A; Braschayko, P; Burke, E; Costello, R; Flynn, J; Haddad, R; Li, Y; Mahadevan, A; Posner, M; Sonis, S; Tishler, RB; Wirth, L	1
Ang, KK; Forastiere, AA; Garden, AS; Harris, J; Kuettel, MR; Myers, JN; Ridge, JA; Rosenthal, DI; Schultz, CJ; Sidhu, K; Trotti, A; Weber, RS	1
Chen, ZG; Choi, M; El-Naggar, AK; Khuri, FR; Muller, S; Papadimitrakopoulou, VA; Saba, NF; Shin, DM; Shin, HJ; Tighiouart, M	1
Chen, ZG; Cho, KJ; Giannakakou, P; Gjyrezi, A; Kim, G; Koenig, L; Li, J; Nie, S; Shin, DM; Shin, HJ; Tighiouart, M; Wang, X; Wang, Y	1
Alcalde, J; Arbea, L; Aristu, J; Cambeiro, M; López-Picazo, JM; Martínez-Monge, R; Moreno-Jiménez, M; Valero, J	1
Anderson, E; Birnbaum, A; Dipetrillo, T; Henderson, D; Joyce, D; Kennedy, T; Puthwala, Y; Rathore, R; Ready, N; Safran, H; Sio, TT; Wanebo, H	1
Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C	1
Allen, AM; Annino, DJ; Busse, PM; Chan, AW; Clark, JR; Goguen, LA; Haddad, RI; Li, Y; Norris, CM; Posner, MR; Tishler, RB; Wirth, LJ	1
Byers, L; El-Naggar, AK; Garden, AS; Gillaspy, KA; Ginsberg, LE; Glisson, BS; Holsinger, FC; Hong, WK; Kies, MS; Lee, JJ; Lewin, JS; Lin, HY; Lippman, SM; Massarelli, E; Papadimitrakopoulou, V; William, WN	1
Day, TA; Garrett-Mayer, E; Gillespie, MB; Sharma, AK; Shirai, K; Wahlquist, AH; Watkins, JM; Zauls, AJ	1
Cozzio, A; Donghi, D; Dummer, R	1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M	2
Dixit, R; Gupta, S; Huilgol, NG	1
Bachelot, T; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Montbarbon, X; Montella, A; Pommier, P; Racadot, S; Zrounba, P	1
Boles Ponto, LL; Buatti, J; Dornfeld, K; Graham, MM; Menda, Y; Sunderland, J; Tewson, TJ; Watkins, GL	1
Bisen, P; Khan, N; Khan, Z; Mouhamad, S; Prasad, GB; Tiwari, RP; Varma, AK	1
Andrews, GA; Fooshee, DR; Frederick, MJ; Galer, C; Milas, ZL; Morrow, PK; Myers, JN; Sano, D; Zhao, M	1
Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I	1
Bergin, P; Damianovich, D; Findlay, M; Hanning, F; Hill, A; McKeage, MJ; Thompson, P	1
Bertholet, V; Dyckhoff, G; Efferth, T; Haefeli, WE; Herold-Mende, C; Ketabi-Kiyanvash, N; Theile, D; Weiss, J	1
Albers, AE; Bas, M; Bergmann, C; Bier, H; Bölke, E; Brandau, S; Greve, J; Hoffmann, TK; Lang, S; Lehnerdt, G; Mattheis, S; Schuler, PJ; Trellakis, S; Whiteside, TL	1
Chang, HL; Donahoe, PK; Li, X; MacLaughlin, DT; Nicolaou, F; Pieretti-Vanmarcke, R; Wei, X	1
Friehs, G; Froelich, K; Hackenberg, S; Hagen, R; Kessler, M; Kleinsasser, N; Koehler, C; Radeloff, A; Scherzed, A	1
Fujii, M; Hasegawa, Y; Kurono, Y; Minami, H; Nibu, K; Onozawa, Y; Sagae, D; Seriu, T; Tahara, M; Tomita, K; Tsukuda, M; Watanabe, A	1
Abo-Elyazeed, A; El-Hadaad, HA; Halim, AA; Wahba, HA	1
Chougule, P; Johnson, TT; Kennedy, T; Marcello, J; Nadeem, A; Radie-Keane, K; Rathore, R; Ready, NE; Ruhl, C; Theall, K; Wanebo, HJ	1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Tsukuda, M	1
Bachar, G; Cohen, K; Feinmesser, R; Hod, R; Katz, O; Mizrachi, A; Peer, D; Shpitzer, T	1
Chougule, P; DiSiena, MR; Koness, RJ; McRae, RG; Nigri, PT; Radie-Keane, K; Rathore, R; Ready, N; Wanebo, HJ	1
Cullen, KJ; Goloubeva, O; Kwok, Y; Ord, R; Parekh, A; Strome, S; Suntharalingam, M; Taylor, R; Wolf, J; Zimrin, A	1
Caicedo-Granados, EE; Lee, GS; Marker, PH; Ondrey, FG; Wuertz, BR	1
Cortes-Funes, H; Cruz-Hernandez, JJ; García-Sáenz, JA; Grau, JJ; Hitt, R; Irigoyen, A	1
Adamo, B; Adamo, V; Denaro, N; Ferraro, P; Franchina, T; Pergolizzi, S; Ricciardi, GR; Santacaterina, A; Settineri, N	1
Aguirre-González, EH; Verduzco-Aguirre, HC; Verduzco-Rodríguez, L	1
Alcalde, J; Aristu, J; Cambeiro, M; Gaztañaga, M; Martínez-Monge, R; Montesdeoca, N; Pagola, M; Rodriguez Ruiz, ME	1
Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ	1
Berlin, JM; Marcano, DC; Milas, L; Myers, JN; Pham, TT; Sano, D; Tour, JM; Valdecanas, DR; Zhou, G	1
Ball, M; Chester, J; Coffey, M; Gore, ME; Hall, GD; Harrington, KJ; Karapanagiotou, EM; Larkin, J; Melcher, AA; Mettinger, K; Newbold, K; Nutting, C; Pandha, HS; Roulstone, V; Syrigos, KN; Tanay, M; Thompson, B; Twigger, K; Vile, RG	1
Colantonio, I; Comino, A; Crook, T; Denaro, N; Gasco, M; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Natoli, G; Russi, E; Syed, N; Vivenza, D	1
Cmelak, AJ; Diaz, R; Kirby, W; Murphy, BA; Murphy, P; Netterville, JL; Shakhtour, B; Shyr, Y; Sinard, RJ; Thorpe, SW; Vlacich, G; Yarbrough, WG	1
Buiret, G; Ceruse, P; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Lavergne, E; Péron, J; Pham, BN; Ramade, A; Zrounba, P	1
Fury, MG; Haque, S; Ho, A; Katabi, N; Kelly, KW; Nwankwo, O; Pfister, DG; Sherman, E; Sima, C	1
Domb, AJ; Kaufman, O; Khan, W; Klapper, L; Levy-Nissenbaum, E; Naftali, E; Pawar, RP; Tabakman, R; Winkler, I	1
Coffey, M; Harrington, KJ; Karapanagiotou, EM; Kyula, JN; Mansfield, D; McLaughlin, M; Melcher, AA; Nuovo, G; Pandha, HS; Pencavel, T; Roulstone, V; Seth, R; Twigger, K; Vile, RG; White, C; Zaidi, S	1
Ahn, SG; Kim, SA; Moon, SM; Yoon, JH	1
Fukao, T; Funato, M; Hirose, Y; Hori, T; Kanda, K; Kaneko, H; Kondo, N; Mizuta, K; Ozeki, M; Sasai, H; Terazawa, D	1
Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T	1
Alba, E; Jiménez, B; Llácer, C; Medina, L; Navarro, V; Pajares, BI; Quero, C; Rueda, A; Sáez, MI; Trigo, JM	1
Akervall, J; Galoforo, S; Geddes, TJ; Grénman, R; Marples, B; Thibodeau, BJ; Wilson, GD	1
Black, AJ; Morris, DG	1
Abhold, E; Altuna, X; Blair, KJ; Fan, JB; Kiang, A; Kuo, SZ; Ongkeko, WM; Rahimy, E; Wang-Rodriguez, J	1
Birnbaum, A; Dipetrillo, T; Follett, N; Joyce, D; Khurshid, H; Luppe, D; Merriam, P; Puthawala, Y; Rathore, R; Safran, H; Sio, TT; Thomas, A; Wanebo, H	1
Barrios, J; Cohen, E; Hansen, CK; Kertsman, J; Kurtsman, J; Lu, H; Tendler, T; Wieder, R	1
Glisson, BS	1
Hong, WK	1
Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W	1
Clayman, G; Diaz, E; Feng, L; Francisco, M; Garden, A; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Kies, MS; Lippman, SM; Myers, J; Papadimitrakopoulou, V; Shin, DM	1
Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M	1
Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S	1
Busse, PM; Case, M; Colevas, AD; Costello, R; Frankenthaler, R; Karp, D; Lake-Willcutt, B; Lamb, CC; Nixon, A; Norris, CM; Posner, MR; Tishler, RB	1
Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E	1
Baredes, S; Bryan, M; Hameed, M; Korah, R; Pavlick, AC; Pliner, L; Saunders, T; Wieder, R	1
Anklesaria, P; Bartholomeusz, C; Bruckheimer, EM; Huang, L; Hung, MC; Li, S; Mebel, E; Paul, R; Ueno, NT; Xia, W; Yo, GH	1
Ensley, JF; Kewson, D; Lonardo, F; Meng, H; Nguyen, T; Oliver, J; Piechocki, MP; Shibuya, TY; Tainsky, MA; Yoo, GH	1
Busse, P; Case, MA; Colevas, AD; Costello, R; Goguen, L; Haddad, R; Lake-Willcutt, B; Norris, CM; Posner, M; Sullivan, C; Tishler, R	1
Brockstein, BE; Fung, BB; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Lefebvre, JL; Posner, MR	1
Odagiri, K; Okami, K; Onuki, J; Sakai, A; Takahashi, M	1
Braaksma, M; Levendag, P	1
Busse, P; Case, MA; Costello, R; Goguen, LA; Haddad, R; Mahadevan, A; Norris, CM; Posner, MR; Sullivan, CA; Tishler, RB; Wirth, L	1
Haddad, R; Posner, M	1
Ahmed, MM; Arnold, S; Chendil, D; Dey, S; Mohiuddin, M; Regine, WF; Spring, PM; Valentino, J	1
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ohnishi, K; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Uto, Y	1
Brockstein, BE; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Rowinsky, EK; Takimoto, CH	1
Dou, QP; Kuhn, DJ; Pross, S; Smith, DM; Whiteside, TL	1
Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN	1
Kanamori, S; Kawamoto, M; Koike, R; Mori, K; Nakamatsu, K; Nishimura, Y; Suzuki, M	1
Lim, JT; Masuda, M; Suzui, M; Weinstein, IB	1
Csuka, O; Koronczay, K; Lövey, J; Németh, G; Remenár, E	1
Becker, A; Bloching, M; Dunst, J; Hänsgen, G; Kuhnt, T; Lotterer, E; Passmann, M; Pelz, T; Pigorsch, S	1
Airoldi, M; Bumma, C; Cortesina, G; Giordano, C; Pedani, F	1
Argiris, A; Brockstein, BE; Haraf, DJ; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Baba, Y; Horiuchi, C; Kato, Y; Mochimatsu, I; Nishimura, G; Taguchi, T; Tanigaki, Y; Tsukuda, M	1
Argiris, A; Forastiere, AA; Langer, CJ; Li, Y; Murphy, BA	1
Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L	1
Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G	1
Ahmed, MM; Arnold, SM; Desimone, P; Kenady, D; Kudrimoti, M; Mohiuddin, M; Regine, WF; Spring, P; Valentino, J	1
Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Daniilidis, J; Dimopoulos, MA; Fountzilas, G; Janinis, J; Kalofonos, HP; Kalogera-Fountzila, A; Makatsoris, T; Nikolaidis, P; Rigatos, SK; Samantas, E; Stathopoulos, GP; Tolis, C	1
Adamo, V; De Renzis, C; Ferraro, G; Pergolizzi, S; Romeo, A; Rossello, R; Santacaterina, A; Sergi, C; Settineri, N; Zanghì, M	1
Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE	1
Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME	1
Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM	1
Chang, TC; Chen, IH; Chen, JS; Liao, CT; Liaw, CC; Tsang, NM; Wang, HM	1
Argiris, A; Forastiere, A; Li, Y	1
Sawamura, D; Shimizu, S; Tsuchiya, K; Yasui, C; Yasukawa, K	1
Bekele, BN; Bucana, CD; Doan, D; Fidler, IJ; Jasser, SA; Myers, JN; Schiff, BA; Yigitbasi, OG; Younes, MN	1
Cooney, MM; Dowlati, A; Hoppel, CL; Ingalls, ST; Ivy, P; Ksenich, P; Lavertu, P; Makar, V; McCrae, K; McPeak, RJ; Overmoyer, B; Remick, S; Tserng, KY	1
Bucci, MK; Devine, P; Hershock, D; Kligerman, MM; Machtay, M; Metz, J; Rosenthal, DI	1
Barone, C; Bertetto, O; Birocco, N; Colantonio, I; Dongiovanni, D; Numico, G; Schena, M	1
Chen, Z; Pribluda, VS; Ricker, JL; Swartz, GM; Van Waes, C; Yang, XP	1
Cohen, RB; DeConti, RC; Forastiere, AA; Jennings, T; Langer, CJ; Li, Y; Nair, S	1
Argyriou, AA; Chroni, E; Ellul, J; Iconomou, G; Kalofonos, HP; Katsoulas, G; Koutras, A; Papapetropoulos, S	1
Hennequin, C	1
Amador, ML; Ballestin, C; Benito, A; Ciruelos, E; Cortes-Funes, H; Hitt, R; Sanchez, JJ	1
Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Stack, BC; Verderame, MF; Zagon, IS	1
Babb, JS; Cheng, J; Cohen, RB; Damsker, JA; Feigenberg, SJ; Horwitz, EM; Kramer, NM; Langer, CJ; Nicolaou, N; Ridge, JA; Sherman, EJ	1
Banglore, M; Jaboin, J; Ord, R; Suntharalingam, M; Taylor, R; Van Echo, D; Wolf, J	1
Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Jaglowski, JR; Leure-duPree, AE; Manning, JD; McLaughlin, PJ; Stack, BC; Verderame, MF; Zagon, IS	1
Schrijvers, D; Vermorken, JB	3
Furutani, K; Fuwa, N; Kodaira, T; Tachibana, H; Yamazaki, T	1
Paredes-Suarez, C; Pestoni, C; Peteiro, C; Toribio, J	1
DeConti, RC; Ensley, J; Forastiere, AA; Gibson, MK; Hussain, MH; Li, Y; Murphy, B	1
Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M	1
Agulnik, M; Feldman, LE; Mundt, AJ; Rhee, EN; Yao, M	1
Argiris, A; Jayaram, P; Pichardo, D	1
Altundag, K; Altundag, O; Mumyakmaz, F; Mumyakmaz, K	1
Arquette, M; Azarnia, N; Dicke, K; Herbst, RS; Hong, WK; Kies, MS; Shin, DM; Vokes, EE	1
Abdel-Wahab, M; Abitbol, A; Hamilton, K; Lewin, A; Markoe, A; Troner, M	1
Cipolat, M; Colantonio, I; Di Costanzo, G; Garrone, O; Gasco, M; Granetto, C; Heouaine, A; Merlano, M; Numico, G; Pelissero, A; Russi, EG; Vigna Taglianti, R	1
Bloching, M; Dunst, J; Haensgen, G; Koesling, S; Kuhnt, T; Mueller, AC; Pelz, T; Schubert, J	1
Athanassiou, E; Bamias, A; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Karanastassi, S; Karina, M; Makatsoris, T; Misailidou, D; Nikolaou, A; Pavlidis, N; Samantas, E; Skarlos, D; Tolis, C; Tsekeris, P; Zamboglou, N	1
Amrein, PC; Clark, JR; Colevas, AD; Deschler, DG; Fabian, RL; Finkelstein, DM; McIntyre, JF; Posner, MR; Rocco, JW; Supko, JG; Wang, CC	1
Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, K; Harvey, M; Lewin, A; Markoe, A; Troner, M; Wu, J	1
Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME	1
Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H	1
Adelstein, DJ	1
Antón, A; Belón, J; Carles, J; Cervantes, A; Chaib, C; Cortés-Funes, H; Escrig, V; Hitt, R; Isla, D; Lobo, F; López-Pousa, A; Martí, JL; Martínez-Trufero, J; Pallarés, C; Pastor, P; Paz-Ares, L; Rizo, A; Sánchez, MA; Valentí, V; Vega, ME	1
Gruensfelder, P; Hoppe, F; Schler, G; Schmidt, M	1
Ishiguro, Y; Kawakami, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M	1
Jaglowski, JR; Stack, BC	1
Biancamano, JD; Gahbauer, RA; Grecula, JC; Jatana, KR; Lang, JC; Schuller, DE; Wang, D	1
Bandobashi, K; Kodama, H; Miyoshi, I; Ohtsuki, Y; Saito, T; Taguchi, H	1
Jing, N; Li, Y; Mao, L; Tweardy, DJ; Yuan, P; Zhu, Q	1
Duffy, K; Friedman, CD; Horwitz, EM; Keenan, E; Langer, CJ; Litwin, S; Nicolaou, N; Ridge, JA; Rosvold, E; Schol, J	1
Amadori, D; Benasso, M; Boni, L; Capaccetti, B; Cavallo, G; Grossi, F; Merlano, M; Numico, G; Ponzanelli, A; Ricci, I; Rosso, R; Taveggia, P; Vigo, V	1
Cho, YB; Kim, SY; Kuh, HJ; Lee, JW; Lee, SH; Park, JK	1
Chmura, SJ; Dekker, A; Garofalo, MC; Haraf, DJ; Jackson, W; Kao, J; List, MA; MacCracken, E; Milano, MT; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Blinder, R; Busse, PM; Goguen, LA; Haddad, RI; Krane, JF; Norris, CM; Posner, MR; Tishler, RB; Wirth, LJ	1
Li, Y; Machtay, M; Wong, SJ	1
Clark, JI; Dakhil, SR; Ensley, J; Hussain, MH; Moon, J; Samlowski, W; Urba, SG; Williamson, S; Worden, FP	1
Angouridakis, N; Aravantinos, G; Bafaloukos, D; Bamias, A; Christodoulou, C; Dafni, U; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Karina, M; Makatsoris, T; Maniadakis, N; Nikolaou, A; Papakostas, P; Pavlidis, N; Stathopoulos, G; Syrigos, K	1
Becker, A; Bloching, M; Dunst, J; Fietkau, R; Klautke, G; Kuhnt, T; Schubert, J	1
Bentzen, JD; Hansen, HS	1
Dietrich, MS; Murphy, BA; Silver, HJ	1
Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y	1
Akhtar, MS; Chougule, PB; Kennedy, T; Koness, J; McRae, R; Nigri, P; Radie-Keane, K; Rathore, R; Ready, N; Wanebo, HJ	1
Agarwala, SS; Argiris, A; Bahri, S; Cano, E; Ferris, R; Heron, DE; Johnson, J; Myers, E; Sandulache, V; Wang, Y	1
Tsukuda, M	2
Carrascosa, LA; Faught, SR; Larocca, RV; Paris, KJ; Spanos, WJ; Yashar, CM	1
Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O	1
Aissat, N; Bieche, I; Faivre, S; Ghoul, A; Le Tourneau, C; Lokiec, F; Raymond, E; Serova, M	1
Ang, K; Curran, W; Harris, J; Horwitz, EM; Kies, M; Langer, CJ; Nicolaou, N; Wong, S	1
Auge, JM; Bernal-Sprekelsen, M; Blanch, JL; Caballero, M; Domingo-Domenech, J; Grau, JJ; Jimenez, W	1
Eisele, DW; Glastonbury, CM; Lin, D; Rafaelian, O; Wang, SJ	1
Cmelak, A; Fakhry, C; Forastiere, A; Gillison, ML; Li, S; Pinto, H; Ridge, JA; Westra, WH	1
Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J	1
Asmar, L; Barrera, D; Boehm, KA; Caracandas, J; Carter, DL; Dakhil, JS; Ilegbodu, D; McCracken, D; O'Rourke, MA; Reid, RL; Rosenberg, RK	1
Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F	1
Creaven, P; Hicks, W; Levine, E; Loewen, G; Meropol, N; Pendyala, L; Perez, R; Raghavan, D	1
Aisner, J; Belani, CP; Conley, B; Egorin, MJ; Engstrom, C; Hiponia, D; Kearns, C; Zuhowski, E	1
Benner, SE; Hong, WK; Huber, MH; Lippman, SM	1
Haraf, DJ; Levin, J; Malone, D; Stenson, K; Stupp, R; Vokes, EE; Weichselbaum, RR	1
Aisner, J; Belani, CP; Conley, B; Gray, W; Hiponia, D; Jacobs, M	1
Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I	1
Asbury, R; Boros, L; Chang, AY; Garrow, G	1
Forastiere, AA; Urba, SG	2
Allen, J; Smith, RE; Thornton, DE	1
Haraf, D; Malone, D; Moran, W; Stupp, R; Sweeney, P; Vokes, EE; Weichselbaum, RR; Wenig, B	1
Close, LG; Fathallah-Skaykh, H; Gazdar, AF; Griener, J; Kamen, B; Lucci, JA; Rosenthal, DI; Schold, SC; Truelson, J; Vuitch, FM	1
Forastiere, AA	4
Schalhorn, B	1
Braakhuis, BJ; Kegel, A; Welters, MJ	1
Adams, G; DeConti, R; Forastiere, AA; Neuberg, D; Taylor, SG	1
Rowinsky, EK	3
Catimel, G; Clavel, M; Franklin, H; Hanauske, A; Kaye, SB; Le Bail, N; Mattijssen, V; Piccart, M; Verweij, J; Wanders, J	1
Donehower, RC; Rowinsky, EK	1
Carbone, DP; Rosenthal, DI	1
Bochtler, H; Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Quasthoff, S; Rastetter, J; Schilling, T	1
Elomaa, L; Grenman, R; Joensuu, H; Martikainen, P; Pulkkinen, JO; Servomaa, K	1
Au, JL; Gan, Y; Schuller, DE; Wientjes, MG	1
Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L	1
Bamberg, M; Belka, C; Bochtler, H; Budach, W; Heinrich, V; Hoffmann, W; Rodemann, HP; Schmidberger, H	2
Alvarez-Vicent, J; Brandariz, A; Colomer, R; Cortés-Funes, H; Hitt, R; Hornedo, J; Mendiola, C; Sevilla, E	1
Arbuck, SG	1
Verweij, J	1
Huang, L; Son, K	1
Hájek, R; Slavik, M; Vorlicek, J	1
Trudeau, ME	1
Kirschner, M; Plasswilm, L; Sauer, R	1
Bunn, PA; Chan, DC; Chou, TC; Kumar, R; Leonard, CE	1
Basu, A; Saijo, N; Weixel, K	1
Griffon-Etienne, G; Marchal, C; Merlin, JL	2
Aisner, J; Cortés-Funes, H	2
Brandariz, A; Colomer, R; Cortés-Funes, H; Hidalgo, M; Hitt, R; Hornedo, J; Peña, M; Vicent, JA	1
Athanassiadis, A; Bacoyiannis, H; Daniilidis, J; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Nikolaou, A; Samantas, E; Skarlos, D; Stathopoulos, G	1
Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME	1
Aisner, J; Conley, B; Gray, W; Jacobs, M; Ord, RA; Suntharalingam, M; Zacharski, D	1
Carbone, DP; Fathallah-Shaykh, H; Gazdar, AF; Griener, J; Hamilton, L; Landay, M; McWhorter, J; Mendelsohn, D; Okani, O; Orr, KY; Rosenthal, DI; Tourville, J; Truelson, JM; Vuitch, FM	1
Cannata, G; Gebbia, N; Gebbia, V; Testa, A	1
Fossella, FV; Hong, WK; Huber, MH; Lee, JS; Lippman, SM; Newman, RA; Wester, M	1
Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Harrison, BR; McDonough, EM; McGrady, MD; Minster, JR; Rodriguez, JJ; Varvares, MA	1
Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Harrison, BR; Hilton, JG; Kim, HJ; McDonough, EM; Minster, JR; Rodriguez, JJ	1
Athanassiades, A; Bacoyiannis, C; Briasoulis, E; Daniilidis, J; Dinopoulou, M; Dombros, N; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Nicolaou, A; Pavlidis, N; Samantas, E; Skarlos, D; Stathopoulos, G	1
Bamberg, M; Belka, C; Bochtler, H; Budach, W; Hess, CF; Hoffmann, W; Schmidberger, H	1
Devriendt, D; Klastersky, J	1
Greco, WR; Levasseur, LM; Rustum, YM; Slocum, HK	1
Fukuda, S; Inuyama, Y; Satoh, N	1
Valero, V	1
Burris, HA	1
Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Kim, HJ; Lowe, V; McDonough, EM; Minster, J; Rodriguez, J; Varvares, MA	1
Akerley, WL; Chougule, P; Cole, B; Koness, RJ; Leone, L; McRae, R; Nigri, P; Ready, N; Safran, H; Wanebo, HJ; Webber, B	1
Capri, G; Cavina, R; Fulfaro, F; Gianni, L; Grandi, C; Licitra, L; Tarenzi, E	1
Alvarez-Vicent, J; Brandariz, A; Colomer, R; Cortés-Funes, H; Hidalgo, M; Hitt, R; Hornedo, J; Paz-Ares, L; Peña, M	1
Boyd, J; Dunleavy, T; Dunphy, F	1
Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D	1
Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lippman, SM; Shin, DM	1
Greco, FA; Hainsworth, JD; Meluch, AA	1
Ensley, J; Hussain, M; Kucuk, O; Salwen, W	1
Benasso, M; Gentile, A; Merlano, M; Numico, G; Ricci, I; Rosso, R	1
Akerley, W; Chougule, P; Cole, B; Koness, RJ; Leone, L; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Safran, H; Wanebo, H	1
Hassan, M; Hoppel, C; Mackay, W; McGloin, B; Mugharbil, A; Olmsted, L; Sharan, V; Steinberg, L; Stepnick, D; Strauss, M; Subramanyan, S	1
Carbone, DP; Corak, J; Frenkel, EP; Gazdar, AF; Griener, J; Kamen, B; Kavanaugh, D; Okani, O; Rosenthal, DI; Sinard, RJ; Vuitch, FM	1
Brockstein, B; Fasanmade, A; Glisson, B; Haraf, DJ; Klepsch, A; Lippman, SM; Ratain, MJ; Stenson, K; Stupp, R; Sulzen, L; Vokes, EE; Weichselbaum, RR	1
Fountzilas, G; Papakostas, P; Rigatos, S; Stathopoulos, GP	1
Ang, KK; Callender, DL; Clayman, GL; Gillenwater, AM; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lee, JJ; Lippman, SM; Papadimitrakopoulou, V; Shin, DM	1
Adak, S; Barton, JJ; Busse, PM; Colevas, AD; Costello, R; Dreyfuss, A; Fabian, RL; Fitzgerald, TJ; Fried, M; Norris, CM; Peters, ES; Posner, MR; Poulin, M; Tishler, RB	1
Dell, J; Gurnani, M; Hajian, G; Lipari, P; Nielsen, LL	1
Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM	2
Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Kemmerich, M; Laubenbacher, C; Quasthoff, S; Theiss, F; Thödtmann, F	1
Adams, G; DeConti, RC; Forastiere, AA; Neuberg, D; Shank, D; Taylor, SG	1
Eisele, DW; Forastiere, AA; Lee, DJ; Westra, WH	1
Colevas, AD; Posner, MR	1
Caldarelli, DD; Coon, JS; Griem, K; Hutchinson, J; Kotelnikov, VM; LaFollette, S; Mundle, S; Panje, W; Preisler, HD; Taylor, S; Wood, N	1
Orel, NF	1
Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M	1
Bömecke, M; Hess, CF; Lehmann, J; Meden, H; Pradier, O; Rave-Fränk, M; Schmidberger, H	1
Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J	1
Lippman, SM; Shin, DM	1
Busse, PM; Colevas, AD; Costello, R; Norris, CM; Peters, ES; Posner, MR; Poulin, M; Rossi, R; Thornhill, L; Tishler, RB	1
Akerley, W; Akhtar, MS; Bellino, J; Chougule, PB; Koness, J; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Safran, H; Wanebo, H	1
DeConti, R; Flood, W; Forastiere, AA; Khuri, F; Lee, DJ; Murphy, B; Spencer, S; Trotti, A; Wheeler, R	1
Brockstein, BE; Haraf, DJ; Vokes, EE; Weichselbaum, RR	1
Akerley, W; Chougule, P; Koness, RJ; Leone, L; McRae, R; Nigri, P; Ready, N; Safran, H; Wanebo, HJ; Webber, B	1
Aviles, V; Carbone, DP; Chalian, AA; Dowell, JE; Machtay, M; Rosenthal, DI; Sinard, R; Weber, RS; Weinstein, GS; Yardley, DA	1
Cook, J; Herscher, LL	1
Bacoyiannis, C; Daniilidis, J; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Kosmidis, P; Nicolaides, C; Nikolaou, A; Papadimitriou, C; Pavlidis, N; Samantas, E; Stathopoulos, G	1
Au, JL; Jang, SH; Kuh, HJ; Weaver, JR; Wientjes, MG	1
Khattab, J; Urba, SG	1
Boyd, JH; Dunleavy, TL; Dunphy, FR; Harrison, BR; Hilton, JG; Rodriguez, JJ	1
Armand, JP; Bordessoule, S; Chouaki, N; Couteau, C; De Forni, M; Domenge, C; Groult, V; Janot, F; Lebecq, A; Leyvraz, S; Oulid-Aissa, D	1
Adak, S; Amrein, P; Barton, J; Colevas, AD; Costello, R; Fried, MP; Gomolin, HI; Lamb, C; Nixon, A; Norris, CM; Posner, MR; Read, R; Tishler, RB	1
Choy, H	1
Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W	1
Agrawal, A; Au, JL; Bauer, CJ; Gahbauer, RA; Grecula, JC; Johnson, A; Martinez-Monge, R; Nag, S; Rhoades, CA; Schuller, DE; Young, D	1
Baylor, A; Cullen, KJ; Forastiere, AA; Heath, EI; Johnston, PG; Langmacher, M; Lee, M; Rasmussen, AA; Shiga, H; Trock, B	1
De Mulder, PH	1
Boyd, JH; Collins, BT; Dunleavy, T; Dunphy, FR; Fletcher, JW; Hollenbeak, C; Kim, H; Lowe, VJ; Martin, D; Stack, BC	1
Shin, DM	1
Achterrath, W; Feldmann, HJ; Heinrich, B; Hesse, K; Kau, R; Molls, M; Sommer, G; Zimmermann, F	1
Janinis, J; Panagos, G	1
Aisner, JA; Conley, BA; Egorin, MJ; Gray, WC; Haas, ML; Herman, JM; Jacobs, MC; Levy, S; Ord, RA; Sivasailam, S; Suntharalingam, M; Van Echo, DA	1
Aviles, V; Chalian, AA; Kligerman, MM; Machtay, M; Mirza, N; Rosenthal, DI; Treat, J; Weber, RS; Weinstein, GS	1
Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E	1
Boddy, AV; Calvert, AH; Griffin, MJ; Hughes, AN; Johnston, A; Kerr, B; Lee, C; Liang, B; Newell, DR	1
Brockstein, B	1
Hauns, B; Holländer, N; Maier-Lenz, H; Mross, K; Schumacher, M	1
Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR	1
Baylor, A; Cullen, KJ; Johnston, PG; Langmacher, M; Lee, M; Rasmussen, AA; Shiga, H	1
Brockstein, B; Haraf, DJ; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RW; Witt, ME	1
Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Ito, K; Kubota, K; Minami, H; Saeki, T; Sasaki, Y; Takashima, S	1
Colevas, AD; Posner, MR; Tishler, RB	1
Blackinton, D; Klostergaard, J; Kouttab, N; Mehta, S; Myrick, D; Omar, I; Wanebo, H	1
Hansen, HS; Larsen, SK; Specht, L	1
Ando, I; Iida, Y; Kusunoki, M; Nakazawa, E; Nishiya, M	1
Agrawal, A; Allen, J; Goldman, FP; Grecula, JC; Rhoades, CA; Schuller, DE; Sharma, P; Smith, RE; Young, D; Zhang, H	1
Barnouin, L; Cals, L; Cupissol, D; Guardiola, E; Guerrier, P; Merad, L; Pivot, X; Savary, J; Schneider, M; Tchiknavorian, X; Thyss, A; Wendling, JL	1
Albert, PS; Boss, C; Cook, JA; Duffey, DC; Figg, WD; Herscher, LL; Kroog, GS; McCullugh, L; Mitchell, JB; Muir, C; Ondrey, FG; Rudy, S; Solomon, BI; Sunwoo, JB; Thomas, GR; Van Waes , C; Zhai, S	1
Ochel, H	1
Conley, BA; Gray, WC; Haas, ML; Haddad, R; Jacobs, MC; Levy, S; Ord, RA; Suntharalingam, M; Van Echo, DA	1
Al-Sarraf, M; Colevas, AD; Frenette, G; Garay, CA; Glisson, B; Norris, CM; Olivares, R; Posner, MR; Seroskie, JD; Shin, DM	1
Adams, GL; DeConti, RC; Forastiere, AA; Leong, T; Murphy, BA; Rowinsky, E; Vlock, DR	1
Fumoleau, P; Schöffski, P; Verweij, J; Wanders, J	1
Carbone, DP; Chalian, AA; Egorin, MJ; Frenkel, EP; Lee, JH; Machtay, M; Miller, LK; Rosen, DM; Rosenthal, DI; Sinard, R; Weber, RS; Weinstein, GS; Yardley, DA	1
Boyd, JH; Dunleavy, TL; Dunphy, FR; Harrison, BR; Kim, HJ; Needles, B; Stack, BC; Trinkaus, KM	1
Boghun, O; Hess, CF; Lehmann, J; Lücke, E; Pradier, O; Rave-Fränk, M; Schmidberger, H	1
Brockstein, B; Chung, T; Haraf, DJ; Kies, MS; List, M; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, A; Rosen, F; Stenson, K; Vokes, EE; Weichselbaum, R	1
Ang, KK; Clayman, G; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lee, JJ; Lippman, SM; Papadimitrakopoulou, VM; Shin, DM	1
Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C	1
Posner, MR	1
Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ	1
Prescott, LM	1
Dokianakis, G; Georgoulias, V; Hatzidaki, D; Janinis, J; Lefantzis, D; Panagos, G; Panousaki, A; Papadakou, M	1
Blackburn, A; Buchanan, A; Cunningham, C; Edelman, G; Kirn, D; Maples, P; Nemunaitis, J; Netto, G; Olson, S; Randlev, B; Tong, A	1
Baker, MN; Burris, HA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH	1
Ackerley, W; Chougule, P; Kennedy, T; Koness, RJ; Leone, L; McRae, R; Nigri, P; Radie-Keane, K; Ready, N; Reiss, P; Safran, H; Wanebo, H	1
Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V	1
Horowitz, J	1
Airoldi, M; Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Recalenda, V; Tagini, V	1
Bidoli, P; Cantù, G; Cerrotta, AM; Damascelli, B; Di Tolla, G; Dosio, F; Frigerio, LF; Garbagnati, F; Lanocita, R; Leo, E; Marchianò, A; Mattavelli, F; Patelli, G; Spreafico, C; Tamplenizza, P; Tichà, V; Vespro, V; Zunino, F	1
Bastian, R; Choudhury, A; Clark, JI; Collins, S; Emami, B; Hofmeister, C; Matz, G; Melian, E; Petruzzelli, G	1
Burkey, BB; Coleman, SC; Day, TA; Netterville, JL; Pietenpol, JA; Stewart, ZA	1
Yokoyama, J	1
Gawecki, W; Golusiński, W; Górecka, KM; Szyfter, K	1
Merlano, M; Numico, G	1
Feher, O; Kowalski, LP; Lima, CA; Martins, SJ; Salvajoli, JV; Simpson, AJ	1
Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA	1
Fuwa, N	1
Adak, S; Colevas, AD; Costello, R; Fried, MP; Goguen, LA; Gopal, HV; Lamb, CC; Norris, CM; Posner, MR; Read, R; Tishler, RB	1
Balcerzak, S; Bender, J; Brooks, R; Chan, KK; D'Ambrosio, S; Gibson-D'Ambrosio, R; Grever, M; Kraut, E; Liu, J; Stanley, H	1
Altun, M; Basaran, M; Bavbek, SE; Demirelli, F; Güllü, I; Onat, H; Sakar, B; Tenekeci, N; Yalçin, S	1
Markman, M; Mekhail, TM	1
Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, KL; Lewin, A; Markoe, A; Rodrigues, MA; Troner, M	1
Cheson, BD	1

Reviews

61 review(s) available for paclitaxel and Cancer of Head

Article	Year
First sonographic description of idiopathic Cutaneous Angiosarcoma of the Head and Neck. Actas dermo-sifiliograficas, 2017, Volume: 108, Issue:10 Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biopsy; Dermatitis, Allergic Contact; Diagnosis, Differential; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms; Ultrasonography, Doppler, Color	2017
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma? Anti-cancer drugs, 2018, Volume: 29, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate	2018
Scalp metastasis from endometrial carcinoma: a case report and literature review. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2018, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Consolidation Chemotherapy; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hysterectomy; Liver Neoplasms; Middle Aged; Obesity; Paclitaxel; Salpingo-oophorectomy; Scalp; Skin Neoplasms	2018
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. Oral oncology, 2018, Volume: 84 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Nivolumab; Organoplatinum Compounds; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Salvage Therapy; Survival Analysis; Treatment Outcome	2018
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review. JAMA otolaryngology-- head & neck surgery, 2016, 09-01, Volume: 142, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids	2016
Molecular targeting agents in the context of primary chemoradiation strategies. Head & neck, 2013, Volume: 35, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease Progression; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2013
Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature. Head & neck, 2013, Volume: 35, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Child; Head and Neck Neoplasms; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Lung Neoplasms; Male; Paclitaxel; Sarcoma, Kaposi	2013
The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:6 Suppl 6 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Radiation-Sensitizing Agents; Taxoids	2002
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome	2002
End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome	2002
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. British journal of cancer, 2003, Jan-13, Volume: 88, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Staging; Paclitaxel; Remission Induction; Taxoids	2003
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. The oncologist, 2003, Volume: 8, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids	2003
Ifosfamide in the treatment of head and neck cancer. Oncology, 2003, Volume: 65 Suppl 2 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome	2003
[Association of taxanes and radiotherapy: preclinical and clinical studies]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured	2004
Taxanes in the treatment of head and neck cancer. Current opinion in oncology, 2005, Volume: 17, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Medical Oncology; Paclitaxel; Taxoids	2005
Revisiting induction chemotherapy for head and neck cancer. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids	2005
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Failure	2006
[Head and neck: molecular-targeted therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines	2007
The role of paclitaxel in the treatment of head and neck cancer. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Tumor Cells, Cultured	1995
Combined modalities in the treatment of head and neck cancers. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Hydroxyurea; Methotrexate; Paclitaxel; Platinum Compounds	1995
Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel	1995
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Infusions, Intravenous; Paclitaxel	1995
Experimental therapeutic approaches for recurrent head and neck cancer. Cancer treatment and research, 1995, Volume: 74 Topics: Amifostine; Animals; Antibodies, Monoclonal; Granulocyte-Macrophage Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Interferon-alpha; Interleukin-2; Paclitaxel; Photochemotherapy	1995
Current and future trials of Taxol (paclitaxel) in head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Forecasting; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic	1994
Update on the antitumor activity of paclitaxel in clinical trials. The Annals of pharmacotherapy, 1994, Volume: 28, Issue:5 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel	1994
Paclitaxel (Taxol) for the treatment of head and neck cancer. Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel	1994
Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Female; Forecasting; Head and Neck Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Thrombocytopenia	1993
An overview of experience with TAXOL (paclitaxel) in the U.S.A. Cancer treatment reviews, 1993, Volume: 19 Suppl C Topics: Breast Neoplasms; Head and Neck Neoplasms; Heart; Humans; Lung Neoplasms; Neoplasms; Nervous System; Paclitaxel; United States	1993
Taxol plus radiation for head and neck cancer. The Journal of infusional chemotherapy, 1995,Spring, Volume: 5, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents	1995
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma, 1996, Volume: 43, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Microtubules; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Paclitaxel	1996
Docetaxel: a review of its pharmacology and clinical activity. The Canadian journal of oncology, 1996, Volume: 6, Issue:1 Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin	1996
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Gynecologic malignancies, head and neck cancer, and other tumor types. Marrakech, Morocco, January 18-20, 1996 and St Croix, V Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Male; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant	1997
Paclitaxel in head and neck and other cancers: future prospects. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant	1997
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Paclitaxel; Urinary Bladder Neoplasms	1997
The taxanes: dosing and scheduling considerations. Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:3 Suppl 2 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel	1997
New cytostatic agents for the treatment of head and neck cancer. Acta oto-rhino-laryngologica Belgica, 1997, Volume: 51, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids	1997
[Head and neck cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Taxoids	1997
Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:8 Suppl 8 Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Mice; Middle Aged; Mucous Membrane; Neoplasms; Neutropenia; Paclitaxel; Taxoids	1997
Paclitaxel pharmacology and other tumor types. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Endometrial Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphoma; Male; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Platinum Compounds; Sarcoma, Kaposi; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	1997
Update on the taxoids and other new agents in head and neck cancer therapy. Current opinion in oncology, 1998, Volume: 10, Issue:3 Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Replication; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Interferon-alpha; Microtubules; Neoplasm Proteins; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome; Tubulin Modulators	1998
Docetaxel in head and neck cancer: a review. American journal of clinical oncology, 1998, Volume: 21, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids	1998
[Taxotere in various solid tumors]. Voprosy onkologii, 1998, Volume: 44, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	1998
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 2 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel	1999
Taxanes as radiosensitizers for head and neck cancer. Current opinion in oncology, 1999, Volume: 11, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents	1999
Chemotherapy in head and neck cancer. Overview of newer agents. Hematology/oncology clinics of North America, 1999, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine	1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. British journal of cancer, 1999, Volume: 81, Issue:3 Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed	1999
Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids	1999
The chemotherapy of head and neck cancer. Acta oto-rhino-laryngologica Belgica, 1999, Volume: 53, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids	1999
Taxoids in head and neck cancer: the American approach. Acta oto-rhino-laryngologica Belgica, 1999, Volume: 53, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States	1999
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local; Paclitaxel; Taxoids	2000
[Recent regimen of chemotherapy for advanced head and neck carcinomas]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Taxoids	2000
Role of taxoids in head and neck cancer. The oncologist, 2000, Volume: 5, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Docetaxel; Head and Neck Neoplasms; Humans; Microtubules; Paclitaxel; Taxoids	2000
[Evidence for Taxotere treatment with solid tumors]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Evidence-Based Medicine; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Stomach Neoplasms; Taxoids	2000
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Seminars in oncology, 2000, Volume: 27, Issue:4 Suppl 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Decision Making; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids	2000
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Seminars in oncology, 2000, Volume: 27, Issue:4 Suppl 8 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2000
Docetaxel in squamous cell cancer of the head and neck. Anti-cancer drugs, 2001, Volume: 12 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids	2001
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Current opinion in molecular therapeutics, 1999, Volume: 1, Issue:4 Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Glioblastoma; Head and Neck Neoplasms; Humans; Injections; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Salvage Therapy; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	1999
[Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Thiosulfates	2002
[Paclitaxel (Taxol) in chemotherapy of head and neck cancer--just another proposal or breakthrough?]. Otolaryngologia polska = The Polish otolaryngology, 2001, Volume: 55, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Head and Neck Neoplasms; Humans; Microtubules; Paclitaxel; Radiation-Sensitizing Agents	2001
[Current and future state of chemoradiotherapy for head and neck cancer]. Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 2002, Volume: 62, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Organoplatinum Compounds; Paclitaxel; Taxoids	2002
Paclitaxel in cancer therapy. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel	2002

Trials

197 trial(s) available for paclitaxel and Cancer of Head

Article	Year
Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma. Carcinogenesis, 2019, Dec-31, Volume: 40, Issue:12 Topics: Adult; Aged; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Drug Resistance, Neoplasm; Extracellular Vesicles; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor beta3	2019
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. Anti-cancer drugs, 2021, 01-01, Volume: 32, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate	2021
Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. Oral oncology, 2021, Volume: 115 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel	2021
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Medical oncology (Northwood, London, England), 2021, Mar-08, Volume: 38, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2021
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Early Termination of Clinical Trials; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Organ Sparing Treatments; Paclitaxel; Panitumumab; Progression-Free Survival; Spain; Squamous Cell Carcinoma of Head and Neck	2021
nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral oncology, 2017, Volume: 72 Topics: Adult; Aged; Albumins; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate	2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 10-01, Volume: 28, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Squamous Cell Carcinoma of Head and Neck	2017
Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma? Pathology oncology research : POR, 2018, Volume: 24, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Lipids; Paclitaxel; Saliva; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2018
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Squamous Cell Carcinoma of Head and Neck	2018
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. Head & neck, 2014, Volume: 36, Issue:7 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Squamous Cell; Drug Delivery Systems; Female; Fibrin Fibrinogen Degradation Products; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Laser-Doppler Flowmetry; Leukocyte Count; Liposomes; Male; Middle Aged; Paclitaxel; Platelet Count; Prospective Studies; Skin; Tumor Necrosis Factor-alpha	2014
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. Head & neck, 2014, Volume: 36, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Deglutition Disorders; Female; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant	2014
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head & neck, 2014, Volume: 36, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2014
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck	2014
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:6 Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endostatins; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult	2014
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-01, Volume: 20, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Tissue Array Analysis	2014
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:13 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2014
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carboplatin; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Epithelial Cells; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel	2014
Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer medicine, 2015, Volume: 4, Issue:4 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome	2015
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma. Head & neck, 2016, Volume: 38 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies	2016
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral oncology, 2016, Volume: 53 Topics: Afatinib; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Quinazolines; Treatment Outcome	2016
Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. Cancer, 2016, 06-01, Volume: 122, Issue:11 Topics: Albumins; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Colorectal Neoplasms; Disaccharides; Enzyme-Linked Immunosorbent Assay; Head and Neck Neoplasms; Humans; Immunoglobulin E; Paclitaxel; Predictive Value of Tests; Prospective Studies; Smoking; Southeastern United States	2016
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral oncology, 2016, Volume: 61 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2016
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. Oral oncology, 2016, Volume: 62 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Panitumumab; Squamous Cell Carcinoma of Head and Neck	2016
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate	2017
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction	2008
A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck. Japanese journal of clinical oncology, 2008, Volume: 38, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Survival Analysis	2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Treatment Outcome	2008
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. American journal of clinical oncology, 2008, Volume: 31, Issue:6 Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis	2008
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anti-cancer drugs, 2009, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome	2009
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer, 2009, Oct-01, Volume: 115, Issue:19 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytokines; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Rate; Xerostomia	2009
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Skin Diseases; Time Factors; Treatment Outcome	2009
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. American journal of clinical oncology, 2010, Volume: 33, Issue:2 Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiodermatitis; Radiotherapy Dosage; Survival Rate; Treatment Outcome	2010
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis	2010
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Panitumumab; Patient Compliance; Radiotherapy, Intensity-Modulated; Treatment Outcome	2010
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-01, Volume: 28, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Papillomaviridae; Prospective Studies	2010
Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time. Cancer biotherapy & radiopharmaceuticals, 2010, Volume: 25, Issue:3 Topics: Aged; Carboplatin; Cisplatin; Dideoxynucleosides; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors	2010
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome	2011
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Young Adult	2012
Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. American journal of clinical oncology, 2012, Volume: 35, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Treatment Outcome	2012
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. International journal of radiation oncology, biology, physics, 2012, Apr-01, Volume: 82, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Prospective Studies; Remission Induction; Squamous Cell Carcinoma of Head and Neck	2012
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome	2012
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. Radiation oncology (London, England), 2011, Nov-22, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies	2011
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Mammalian orthoreovirus 3; Middle Aged; Nausea; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Stomatitis; Treatment Outcome	2012
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hyperglycemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome	2012
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer, 2013, Feb-15, Volume: 119, Issue:4 Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Osteonectin; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Suppressor Proteins	2013
Clinical trials involving the oncolytic virus, reovirus: ready for prime time? Expert review of clinical pharmacology, 2012, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Mammalian orthoreovirus 3; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Severity of Illness Index; Treatment Outcome	2012
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. American journal of clinical oncology, 2014, Volume: 37, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Survival Analysis; Treatment Outcome	2014
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer, 2002, Jun-01, Volume: 94, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome	2002
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer, 2002, Jul-15, Volume: 95, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Mesna; Middle Aged; Paclitaxel; Survival Rate; Taxoids	2002
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome	2002
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids	2002
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology, 2002, Volume: 63, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors	2002
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas. American journal of clinical oncology, 2002, Volume: 25, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Isotretinoin; Male; Middle Aged; Paclitaxel; Remission Induction; Uterine Cervical Neoplasms	2002
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotection; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiotherapy, Conformal; Tomography, X-Ray Computed; Xerostomia	2002
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Erythropoietin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Rate; Treatment Outcome	2003
Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Japanese journal of clinical oncology, 2003, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis; Taxoids	2003
Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2003, Volume: 68, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Survival Rate	2003
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Cohort Studies; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neoplasm Metastasis; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Analysis; Time Factors	2003
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome	2004
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Xerostomia	2003
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral oncology, 2004, Volume: 40, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome	2004
Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. International journal of radiation oncology, biology, physics, 2004, Apr-01, Volume: 58, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Treatment Outcome	2004
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anti-cancer drugs, 2004, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome	2004
Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Dosage; Treatment Outcome	2004
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Treatment Outcome	2004
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome	2004
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer, 2004, Aug-15, Volume: 101, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Sepsis; Survival Analysis; Treatment Outcome	2004
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles	2005
Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. American journal of clinical oncology, 2004, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis	2004
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Vomiting	2005
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer investigation, 2004, Volume: 22, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studies; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	2004
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology, 2005, Jan-11, Volume: 64, Issue:1 Topics: Administration, Oral; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Testicular Neoplasms; Uterine Cervical Neoplasms; Vitamin E	2005
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Remission Induction; Tumor Suppressor Protein p53	2005
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head & neck, 2005, Volume: 27, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Follow-Up Studies; Head and Neck Neoplasms; Humans; Nausea; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Retreatment; Salvage Therapy; Stomatitis; Vomiting	2005
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucous Membrane; Paclitaxel; Radiotherapy Dosage	2004
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. International journal of radiation oncology, biology, physics, 2005, Mar-15, Volume: 61, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage	2005
Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prospective Studies	2005
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome	2005
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Treatment Outcome	2005
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Logistic Models; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome	2005
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Eruptions; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Radiotherapy, Adjuvant; Surveys and Questionnaires; Survival Rate	2005
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2005, Volume: 75, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2005
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Treatment Outcome	2005
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome	2005
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. American journal of clinical oncology, 2005, Volume: 28, Issue:5 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel	2005
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Anti-cancer drugs, 2005, Volume: 16, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel	2005
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Spain; Survival Analysis; Treatment Outcome	2005
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Cancer investigation, 2006, Volume: 24, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Ear Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Recombinant Proteins; Salivary Gland Neoplasms; Survival Analysis	2006
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2006
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. International journal of oncology, 2006, Volume: 28, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Survival Analysis	2006
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer, 2006, Jul-15, Volume: 107, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome	2006
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Polyethylene Glycols; Survival Analysis; Treatment Outcome	2006
Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors. Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy; Treatment Outcome	2006
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head & neck, 2007, Volume: 29, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome	2007
Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). Head & neck, 2008, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neck Dissection; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage; Survival Rate	2008
Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Time	2007
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Mucositis; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Xerostomia	2007
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	2007
Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Archives of otolaryngology--head & neck surgery, 2007, Volume: 133, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute, 2008, Feb-20, Volume: 100, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Human papillomavirus 16; Humans; In Situ Hybridization; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Papillomavirus Infections; Polymerase Chain Reaction; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome	2008
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids	2008
Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. Investigational new drugs, 2008, Volume: 26, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis	2008
Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel	1995
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Radiotherapy Dosage	1995
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Premedication	1995
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids	1995
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction	1995
A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Adult; Aged; Carcinoma, Squamous Cell; Cytokines; Female; Head and Neck Neoplasms; Humans; Interleukin-1; Male; Microtubules; Middle Aged; Paclitaxel; Remission Induction; Tumor Necrosis Factor-alpha	1995
Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors. Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9 Topics: Anemia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphopenia; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Uterine Cervical Neoplasms	1995
Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. Journal of the National Cancer Institute. Monographs, 1993, Issue:15 Topics: Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Paclitaxel	1993
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:6 Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Europe; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Taxoids	1994
Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 14 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction	1995
Docetaxel: an active drug for squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome	1996
[Preclinical and clinical results in the simultaneous radiochemotherapy of head and neck tumors with Paclitaxel]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1996, Volume: 172 Suppl 1 Topics: Adult; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Treatment Outcome; Tumor Cells, Cultured	1996
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 15 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Remission Induction; Treatment Outcome	1995
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Anti-cancer drugs, 1995, Volume: 6 Suppl 4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sarcoma; Taxoids	1995
Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1996, Volume: 172, Issue:10 Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Time Factors	1996
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Treatment Outcome	1997
Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction	1997
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction	1997
Paclitaxel in simultaneous radiochemotherapy of head and neck cancer: preclinical and clinical results. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fibroblasts; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Tumor Cells, Cultured	1997
A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiotherapy, Adjuvant	1997
Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Survival Analysis	1997
Single agent paclitaxel in advanced squamous cell head and neck carcinoma. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:5 Topics: Aged; Antineoplastic Agents, Phytogenic; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel	1996
A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Synergism; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasms; Paclitaxel	1996
Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer, 1997, Apr-15, Volume: 79, Issue:8 Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Erythrocyte Transfusion; Erythropoietin; Head and Neck Neoplasms; Hemoglobin A; Humans; Middle Aged; Paclitaxel; Recombinant Proteins	1997
A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer, 1997, May-15, Volume: 79, Issue:10 Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cohort Studies; Combined Modality Therapy; Female; Fever; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Preoperative Care; Survival Rate; Thrombocytopenia	1997
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel	1997
Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial. International journal of radiation oncology, biology, physics, 1997, Jul-01, Volume: 38, Issue:4 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Stomatitis	1997
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:8 Suppl 8 Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids	1997
Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. American journal of surgery, 1997, Volume: 174, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Preoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate	1997
Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Palliative Care; Treatment Outcome	1997
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Survival Rate	1997
Paclitaxel and carboplatin in head and neck cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Female; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel; Premedication; Treatment Outcome	1997
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel	1997
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	1997
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome	1997
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects	1997
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Hemoglobinometry; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Platelet Count	1997
Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome	1997
A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cells, Cultured; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Mitotic Index; Paclitaxel; Survival Rate; Tumor Cells, Cultured	1997
Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Erythropoietin; Female; Head and Neck Neoplasms; Hemoglobinometry; Humans; Infusions, Intravenous; Male; Paclitaxel	1997
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Prognosis	1998
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids	1998
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Paclitaxel; Taxoids	1998
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	1998
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome	1998
Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer, 1998, Jun-01, Volume: 82, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel	1998
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. Head & neck, 1998, Volume: 20, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Culture Techniques; Diagnosis, Differential; Female; Fibrosis; Fluorouracil; Granuloma, Foreign-Body; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neck; Neck Dissection; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Registries; Remission Induction; Tirapazamine; Triazines	1998
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Count; Cell Division; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Paclitaxel; S Phase; Time Factors	1996
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids	1999
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome	1999
Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Confidence Intervals; Female; Head and Neck Neoplasms; Humans; Male; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome	1999
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Treatment Outcome	1999
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Paclitaxel; Survival Analysis; Treatment Outcome	1999
Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Postoperative Complications; Preoperative Care; Prospective Studies; Survival Analysis; Treatment Outcome	1999
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Home Infusion Therapy; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Sensitizing Agents	1999
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate	1999
Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer, 1999, Oct-01, Volume: 86, Issue:7 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Erythropoietin; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies	1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. British journal of cancer, 1999, Volume: 81, Issue:3 Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed	1999
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Mouth Mucosa; Nausea; Paclitaxel; Stomatitis; Taxoids	1999
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer, 1999, Dec-01, Volume: 86, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome	1999
Intensification regimen 2 for advanced head and neck squamous cell carcinomas. Archives of otolaryngology--head & neck surgery, 1999, Volume: 125, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Survival Rate	1999
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Glutathione S-Transferase pi; Glutathione Transferase; Head and Neck Neoplasms; Humans; Isoenzymes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Tumor Suppressor Protein p53	1999
Surveillance for recurrent head and neck cancer using positron emission tomography. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Tomography, Emission-Computed	2000
Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2000, Volume: 176, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome	2000
A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer. International journal of radiation oncology, biology, physics, 1999, May-01, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis	1999
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. American journal of clinical oncology, 2000, Volume: 23, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids	2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. British journal of cancer, 2000, Volume: 82, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Monitoring; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Quinazolines; Tumor Cells, Cultured	2000
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome	2000
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Prognosis; Recombinant Proteins	2000
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids	2000
Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck. Cancer, 2000, Dec-15, Volume: 89, Issue:12 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome	2000
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology, 2001, Volume: 60, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome	2001
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Cycle; Combined Modality Therapy; Deglutition; Disease-Free Survival; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Radiation-Sensitizing Agents; Speech; Survival Rate	2001
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer, 2001, Feb-01, Volume: 91, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prognosis; Treatment Outcome	2001
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypocalcemia; Magnesium; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids	2001
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel	2001
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis	2001
Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999. Cancer, 2001, Mar-01, Volume: 91, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome	2001
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Illinois; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis	2001
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer, 2001, Apr-01, Volume: 91, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	2001
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome	2001
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. American journal of clinical oncology, 2001, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids	2001
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene therapy, 2001, Volume: 8, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoviridae; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Colonic Neoplasms; Feasibility Studies; Female; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Paclitaxel; Thyroid Neoplasms	2001
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer, 2001, Aug-01, Volume: 92, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2001
Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Annals of surgical oncology, 2001, Volume: 8, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Recovery of Function; Severity of Illness Index; Survival Rate; Treatment Outcome	2001
A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco (Societa chimica italiana : 1989), 2001, Volume: 56, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2001
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical acti Cancer, 2001, Nov-15, Volume: 92, Issue:10 Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Anus Neoplasms; Carcinoma, Squamous Cell; Castor Oil; Chemistry, Pharmaceutical; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neutropenia; Paclitaxel; Particle Size; Surface-Active Agents; Treatment Outcome	2001
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer, 2001, Nov-01, Volume: 92, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome	2001
Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck. Head & neck, 2002, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiotherapy; Radiotherapy Dosage; Survival Rate	2002
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome	2002
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). American journal of clinical oncology, 2002, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids	2002
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; DNA Adducts; Dose-Response Relationship, Drug; Drug Interactions; Head and Neck Neoplasms; Humans; Leukocytes; Mass Spectrometry; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Reproducibility of Results	2002
A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	2002
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. International journal of radiation oncology, biology, physics, 2002, Jul-15, Volume: 53, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Time Factors; Treatment Outcome	2002

Other Studies

201 other study(ies) available for paclitaxel and Cancer of Head

Article	Year
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of medicinal chemistry, 2015, Dec-10, Volume: 58, Issue:23 Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; Microtubules; Neoplasm Transplantation; Structure-Activity Relationship; Tubulin; Tubulin Modulators	2015
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1. Oral diseases, 2023, Volume: 29, Issue:2 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fluorouracil; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Orlistat; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2023
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 12-15, Volume: 27, Issue:24 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Paclitaxel; Pancreatic Neoplasms; Transforming Growth Factor beta	2021
Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer. Oral oncology, 2021, Volume: 123 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel	2021
AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cellular oncology (Dordrecht), 2022, Volume: 45, Issue:1 Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptors, Fibroblast Growth Factor; SOXB1 Transcription Factors	2022
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma. Oral oncology, 2022, Volume: 127 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2022
Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report. Anti-cancer drugs, 2022, 08-01, Volume: 33, Issue:7 Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment	2022
miR-211-3p enhances induction chemotherapy insensitivity by upregulating CSF2/CCL20/TNF signaling in hypopharyngeal squamous cell carcinoma. Molecular biology reports, 2022, Volume: 49, Issue:7 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL20; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Ligands; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tumor Necrosis Factors	2022
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & neck, 2022, Volume: 44, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Frail Elderly; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2022
Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer. Cancer reports (Hoboken, N.J.), 2023, Volume: 6, Issue:1 Topics: Adult; Carboplatin; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2023
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. PloS one, 2022, Volume: 17, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2022
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer. Journal of the Egyptian National Cancer Institute, 2023, Jan-19, Volume: 35, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life	2023
A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis-Targeting Chimeras Enhanced Immunotherapy. Advanced materials (Deerfield Beach, Fla.), 2023, Volume: 35, Issue:12 Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Nanogels; Paclitaxel; Proteolysis; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment	2023
Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy. PloS one, 2023, Volume: 18, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Muscle, Skeletal; Paclitaxel; Retrospective Studies	2023
Private Payer-Negotiated Rates for FDA-Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2023, Volume: 169, Issue:4 Topics: Antineoplastic Agents; Biological Products; Carboplatin; Cross-Sectional Studies; Head and Neck Neoplasms; Humans; Immunotherapy; Nivolumab; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2023
Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy. Drug delivery, 2023, Volume: 30, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Mice; Nanoparticles; Paclitaxel; Polyethylene Glycols; Reactive Oxygen Species	2023
Integrated multi-omics analysis reveals unique signatures of paclitaxel-loaded poly(lactide-co-glycolide) nanoparticles treatment of head and neck cancer cells. Proteomics, 2023, Volume: 23, Issue:16 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Head and Neck Neoplasms; Humans; Lactic Acid; Multiomics; Nanoparticles; Paclitaxel; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tandem Mass Spectrometry	2023
Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). International journal of surgery (London, England), 2023, Aug-01, Volume: 109, Issue:8 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Microenvironment	2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & neck, 2023, Volume: 45, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2023
Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2023, Volume: 48, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2023
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study. Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Laryngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2023
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Oral oncology, 2023, Volume: 147 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2023
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Oral oncology, 2019, Volume: 98 Topics: Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Genotype; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Multidrug Resistance-Associated Protein 2; Odds Ratio; Paclitaxel; Pharmacogenomic Variants; Polymorphism, Single Nucleotide	2019
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. Medical oncology (Northwood, London, England), 2019, Oct-08, Volume: 36, Issue:11 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Papillomavirus Infections; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2019
Anticancer effects of NSC‑631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression. Oncology reports, 2020, Volume: 43, Issue:1 Topics: Antineoplastic Agents; Berberine Alkaloids; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Paclitaxel; Phenanthridines	2020
Combined nab-paclitaxel and irradiation for large cutaneous angiosarcoma of the face and scalp with pulmonary metastases. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:7 Topics: Aged; Albumins; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Scalp; Skin Neoplasms	2020
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. International journal of clinical oncology, 2020, Volume: 25, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2020
Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer, 2021, 02-15, Volume: 127, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Carboplatin; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Magnesium Deficiency; Male; Middle Aged; Paclitaxel; Prognosis	2021
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy. Journal of cancer research and therapeutics, 2020, Volume: 16, Issue:Supplement Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perfusion Imaging; Prognosis; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Young Adult	2020
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient. Anti-cancer drugs, 2021, 06-01, Volume: 32, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Frailty; Head and Neck Neoplasms; Humans; Malnutrition; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2021
Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trials. Oral oncology, 2021, Volume: 116 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Head and Neck Neoplasms; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2021
Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma. International journal of clinical oncology, 2021, Volume: 26, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2021
Effectual nanotherapy against oral squamous cell carcinoma. Drug development and industrial pharmacy, 2021, Volume: 47, Issue:5 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Folic Acid; Head and Neck Neoplasms; Mouth Neoplasms; Nanoparticles; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tissue Distribution	2021
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. Cancer medicine, 2021, Volume: 10, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidence Intervals; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Progression-Free Survival; Propensity Score; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2021
Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: Drug delivery, 2021, Volume: 28, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Carriers; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Polymers; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays	2021
PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma. Anticancer research, 2021, Volume: 41, Issue:7 Topics: Apoptosis; Cell Line, Tumor; Cetuximab; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Squamous Cell Carcinoma of Head and Neck	2021
Patterns of Care for Elderly Patients With Locally Advanced Head and Neck Cancer. International journal of radiation oncology, biology, physics, 2017, 07-15, Volume: 98, Issue:4 Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Decision Making; Delivery of Health Care; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Middle Aged; Odds Ratio; Paclitaxel; Radiotherapy; Regression Analysis	2017
Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer. Drug delivery, 2016, Volume: 24, Issue:1 Topics: Animals; Cell Line, Tumor; Cisplatin; Drug Carriers; Folic Acid; Head and Neck Neoplasms; Lipids; Mice; Paclitaxel	2016
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. Oral oncology, 2017, Volume: 73 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck	2017
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible. Anticancer research, 2018, Volume: 38, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck	2018
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. International journal of oncology, 2018, Volume: 52, Issue:2 Topics: B7-H1 Antigen; Carcinoma, Squamous Cell; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Female; Head and Neck Neoplasms; Humans; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment	2018
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral oncology, 2018, Volume: 80 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck	2018
Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. Anti-cancer drugs, 2019, Volume: 30, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cetuximab; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Nivolumab; Paclitaxel; Prognosis	2019
Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. Oncology research and treatment, 2018, Volume: 41, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Deglutition Disorders; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck	2018
Towards risk-stratified induction regimens. Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome	2019
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Auris, nasus, larynx, 2020, Volume: 47, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nivolumab; Oxonic Acid; Paclitaxel; Palliative Care; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Failure	2020
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines. Anticancer research, 2019, Volume: 39, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cisplatin; Doxorubicin; Fluorouracil; Head and Neck Neoplasms; Humans; Methadone; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2019
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5 Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Paclitaxel; Pregnane X Receptor; Real-Time Polymerase Chain Reaction; Receptors, Steroid; Rifampin	2013
Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2014, Volume: 271, Issue:2 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Failure; Treatment Outcome	2014
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. Oncology, 2013, Volume: 84, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Fluorouracil; Germany; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Markov Chains; Monte Carlo Method; Neoadjuvant Therapy; Paclitaxel	2013
Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy. Oncology nursing forum, 2013, Volume: 40, Issue:6 Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Cancer Care Facilities; Carboplatin; Chemoradiotherapy; Dehydration; Gastrointestinal Diseases; Head and Neck Neoplasms; Hospitalization; Humans; Middle Aged; Mucositis; Nurse Practitioners; Outpatient Clinics, Hospital; Paclitaxel; Pain; Patient Compliance; Program Evaluation; Retrospective Studies; Treatment Outcome	2013
Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. International journal of radiation oncology, biology, physics, 2013, Nov-15, Volume: 87, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cone-Beam Computed Tomography; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Organs at Risk; Oropharyngeal Neoplasms; Paclitaxel; Parotid Gland; Prospective Studies; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy Setup Errors; Radiotherapy, Intensity-Modulated; Saliva; Salivation	2013
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral oncology, 2014, Volume: 50, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids	2014
Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds. Biomedical materials (Bristol, England), 2013, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents; Bombyx; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Extracellular Matrix; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Paclitaxel; Phenotype; Silk; Tissue Engineering; Tissue Scaffolds	2013
Unresectable angiosarcoma treated with bevacizumab and paclitaxel. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Paclitaxel; Remission Induction; Scalp; Skin Neoplasms	2014
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer biology & therapy, 2014, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Heterografts; Humans; Ki-67 Antigen; Mice, Inbred NOD; Mice, SCID; Multidrug Resistance-Associated Proteins; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2014
Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Molecular pharmaceutics, 2014, Apr-07, Volume: 11, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dimyristoylphosphatidylcholine; Doxorubicin; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Paclitaxel; Polymethacrylic Acids; Squamous Cell Carcinoma of Head and Neck	2014
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. The British journal of dermatology, 2014, Volume: 171, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome	2014
Nanoparticle albumin-bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin. Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:11 Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antineoplastic Agents, Phytogenic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Scalp; Skin Neoplasms	2015
Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:11 Topics: Aged; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck	2014
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity. Oncotarget, 2015, Jan-20, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Ephrin-B1; Head and Neck Neoplasms; HEK293 Cells; Human papillomavirus 6; Humans; Immunoblotting; MCF-7 Cells; Mice, Inbred C57BL; Microscopy, Confocal; Microtubule-Associated Proteins; Microtubules; Oncogene Proteins, Viral; Paclitaxel; Protein Binding; Repressor Proteins; RNA Interference; Taxoids	2015
p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer. The Annals of otology, rhinology, and laryngology, 2015, Volume: 124, Issue:9 Topics: Adult; Antineoplastic Agents; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Gene Expression Profiling; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomavirus Infections; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome	2015
Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience. Auris, nasus, larynx, 2016, Volume: 43, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Child; Cisplatin; Disease-Free Survival; Ear Canal; Ear Neoplasms; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Otologic Surgical Procedures; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tertiary Care Centers; Treatment Outcome; Young Adult	2016
[Chemotherapy with paclitaxel leads to microRNA release]. HNO, 2015, Volume: 63, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy; Head and Neck Neoplasms; Humans; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 118, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genetic Therapy; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Lentivirus; Mice; Mice, Nude; Neoplasm Proteins; Paclitaxel; Radiation Tolerance; RNA, Small Interfering; Survivin; Xenograft Model Antitumor Assays	2016
Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. Radiation oncology (London, England), 2016, Jan-20, Volume: 11 Topics: Aged; Brachytherapy; Carcinoma, Squamous Cell; Cetuximab; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome	2016
Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b. Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:6 Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Apoptotic Protease-Activating Factor 1; Carcinoma, Squamous Cell; Caspase 9; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Methylation; Enzyme Activation; Head and Neck Neoplasms; Humans; Membrane Potential, Mitochondrial; Paclitaxel; Promoter Regions, Genetic; Squamous Cell Carcinoma of Head and Neck; Staurosporine	2016
Induction chemotherapy before surgery for unresectable head and neck cancer. B-ENT, 2016, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Oropharyngeal Neoplasms; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome	2016
Anticancer activity of drug conjugates in head and neck cancer cells. Frontiers in bioscience (Elite edition), 2016, 06-01, Volume: 8, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cysteine; Esters; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Papillomavirus Infections; Sexually Transmitted Diseases	2016
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:S3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids	2016
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. Molecular cancer therapeutics, 2016, Volume: 15, Issue:9 Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Chemoradiotherapy; Combined Modality Therapy; Disease Models, Animal; Female; Head and Neck Neoplasms; Humans; Mice; Mitosis; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Xenograft Model Antitumor Assays	2016
Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate	2016
Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors. Journal of ethnopharmacology, 2016, Nov-04, Volume: 192 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bassia scoparia; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Fruit; Head and Neck Neoplasms; Humans; Male; Methanol; Mice, Inbred C3H; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Poly(ADP-ribose) Polymerases; Signal Transduction; Solvents; Squamous Cell Carcinoma of Head and Neck; Tumor Burden	2016
Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. Anticancer research, 2016, Volume: 36, Issue:10 Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Head and Neck Neoplasms; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2016
Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma. Cancer research, 2017, 01-15, Volume: 77, Issue:2 Topics: Animals; Antineoplastic Agents; ARNTL Transcription Factors; Blotting, Western; Carcinogenesis; Carcinoma, Squamous Cell; Chromatin Immunoprecipitation; Circadian Clocks; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Polymerase Chain Reaction; Squamous Cell Carcinoma of Head and Neck; Tongue Neoplasms; Xenograft Model Antitumor Assays	2017
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. Cancer medicine, 2017, Volume: 6, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult	2017
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:2 Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids	2017
Congenital angiosarcoma with transient response to paclitaxel. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Diagnosis, Differential; Fatal Outcome; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Immunohistochemistry; Infant; Lymphangioma, Cystic; Paclitaxel	2008
Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center. Critical reviews in oncology/hematology, 2008, Volume: 67, Issue:3 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thoracic Neoplasms; Treatment Outcome; Urogenital Neoplasms	2008
Craniocervical paraganglioma with numerous pulmonary metastases--case report. Neurologia medico-chirurgica, 2008, Volume: 48, Issue:9 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glomus Jugulare Tumor; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Paclitaxel; Paraganglioma; Treatment Outcome	2008
Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. International journal of radiation oncology, biology, physics, 2008, Dec-01, Volume: 72, Issue:5 Topics: Adult; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Volume; Carboplatin; Cetuximab; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Predictive Value of Tests; Radiotherapy Dosage; Time Factors; Treatment Failure; Treatment Outcome	2008
Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head & neck, 2009, Volume: 31, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carrier Proteins; Female; Folate Receptors, GPI-Anchored; Folic Acid; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Nanomedicine; Nanotechnology; Paclitaxel; Receptors, Cell Surface; Young Adult	2009
Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp. The British journal of dermatology, 2009, Volume: 160, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Facial Neoplasms; Forehead; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Paclitaxel; Scalp; Treatment Outcome	2009
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head & neck, 2009, Volume: 31, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Aurora Kinases; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Flow Cytometry; G1 Phase; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Immunohistochemistry; Paclitaxel; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Cells, Cultured	2009
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2009, Jul-15, Volume: 74, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Fibrosis; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Skin; Survival Rate; Treatment Outcome	2009
Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. International journal of cancer, 2009, May-01, Volume: 124, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cisplatin; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Middle Aged; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Nitrites; Nitroprusside; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S-Nitroso-N-Acetylpenicillamine; Survivin; Umbilical Veins	2009
Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2009, Volume: 38, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases	2009
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. International journal of oncology, 2009, Volume: 34, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cisplatin; Drug Interactions; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Oxides; Paclitaxel; Poly(ADP-ribose) Polymerases; Stomach Neoplasms; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms	2009
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope, 2009, Volume: 119, Issue:8 Topics: Aged; Aged, 80 and over; Analysis of Variance; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Palliative Care; Polymorphism, Single Nucleotide; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Survival Analysis; Treatment Outcome	2009
Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Hypothyroidism; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiography; Radiotherapy, Intensity-Modulated; Retrospective Studies; Risk Factors; Taxoids; Thyroid Gland	2010
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity. International journal of radiation oncology, biology, physics, 2010, Volume: 76, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Tumor Burden	2010
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclooxygenase 2; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hyperplasia; Ifosfamide; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Precancerous Conditions; Prognosis; Survival Rate	2009
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS nano, 2009, Oct-27, Volume: 3, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Carrier Proteins; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Carriers; Female; Folate Receptors, GPI-Anchored; Folic Acid; Head and Neck Neoplasms; Heparin; Humans; Mice; Microtubules; Nanomedicine; Nanoparticles; Paclitaxel; Particle Size; Receptors, Cell Surface; Tissue Distribution	2009
Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. American journal of clinical oncology, 2010, Volume: 33, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome	2010
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. The Laryngoscope, 2010, Volume: 120, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiation Injuries; Survival Rate	2010
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. The British journal of dermatology, 2010, Volume: 162, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome	2010
Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncology reports, 2010, Volume: 23, Issue:2 Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Promoter Regions, Genetic; Telomerase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2010
Chemoradiation with hyperthermia in the treatment of head and neck cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2010, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies	2010
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncology reports, 2010, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2010
Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. Anti-cancer drugs, 2010, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome	2010
Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel. Current cancer drug targets, 2010, Volume: 10, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Survivin	2010
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head & neck, 2011, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Disease Models, Animal; ErbB Receptors; Flow Cytometry; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Random Allocation; Sensitivity and Specificity; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2011
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins. BMC cancer, 2010, Aug-23, Volume: 10 Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome	2010
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC cancer, 2010, Aug-23, Volume: 10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Motor Neuron Disease; Neoplasm Staging; Neurophysiology; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome	2010
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head & neck, 2011, Volume: 33, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Head and Neck Neoplasms; Humans; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Squamous Cell Carcinoma of Head and Neck	2011
In vitro chemosensitivity of head and neck cancer cell lines. European journal of medical research, 2010, Aug-20, Volume: 15, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Methotrexate; Paclitaxel	2010
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecologic oncology, 2011, Volume: 120, Issue:1 Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Head and Neck Neoplasms; Humans; Neoplasm Invasiveness; Neoplasms; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta	2011
BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro. Cancer biology & therapy, 2011, Feb-01, Volume: 11, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Mesenchymal Stem Cells; Paclitaxel	2011
Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines. Auris, nasus, larynx, 2011, Volume: 38, Issue:5 Topics: Adenoviridae Infections; Adenovirus E1A Proteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, myc; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Receptors, Virus; RNA, Messenger; S Phase; Squamous Cell Carcinoma of Head and Neck; Streptolysins; Telomerase	2011
Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials, 2011, Volume: 32, Issue:21 Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Carriers; Female; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Hyaluronic Acid; Male; Materials Testing; Mice; Middle Aged; Mitomycin; Nanostructures; Paclitaxel; Particle Size	2011
Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. Annals of surgical oncology, 2011, Volume: 18, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gamma Rays; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Preservation; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome	2011
The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. Archives of otolaryngology--head & neck surgery, 2011, Volume: 137, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; I-kappa B Proteins; Indomethacin; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Transfection	2011
Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Multimodal Imaging; Paclitaxel; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome	2011
Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer. Head & neck, 2012, Volume: 34, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage	2012
Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo. ACS nano, 2012, Mar-27, Volume: 6, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Drug Carriers; Head and Neck Neoplasms; Humans; Male; Mice; Nanostructures; Paclitaxel; Polyethylene Glycols; Tumor Burden	2012
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral oncology, 2012, Volume: 48, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Young Adult	2012
Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. The oncologist, 2012, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2012
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anti-cancer drugs, 2012, Volume: 23, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Failure	2012
Pharmacokinetic and efficacy study of cisplatin and paclitaxel formulated in a new injectable poly(sebacic-co-ricinoleic acid) polymer. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 82, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decanoic Acids; Delayed-Action Preparations; Head and Neck Neoplasms; Humans; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Male; Mice; Mice, Nude; Paclitaxel; Polymers; Rats; Ricinoleic Acids; Xenograft Model Antitumor Assays	2012
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene therapy, 2013, Volume: 20, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Orthoreovirus; Paclitaxel	2013
HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression. The Journal of biological chemistry, 2012, Oct-12, Volume: 287, Issue:42 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Response Elements; Sequence Deletion	2012
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral oncology, 2013, Volume: 49, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence	2013
Isolation and genomic characterization of stem cells in head and neck cancer. Head & neck, 2013, Volume: 35, Issue:11 Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cell Separation; Cisplatin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genomics; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Paclitaxel; Radiation Tolerance; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured	2013
Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC cancer, 2012, Nov-24, Volume: 12 Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Interactions; Enzyme Activation; Epithelial-Mesenchymal Transition; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; MicroRNAs; Mitogen-Activated Protein Kinase 7; Neoplastic Stem Cells; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrans; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck	2012
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling. Anticancer research, 2013, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Collagen Type I; Drug Resistance, Neoplasm; Fibronectins; Head and Neck Neoplasms; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Signal Transduction	2013
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:6 Suppl 6 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids	2002
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer research, 2002, Nov-15, Volume: 62, Issue:22 Topics: Adenovirus E1A Proteins; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Combined Modality Therapy; DNA; Genetic Therapy; Head and Neck Neoplasms; Humans; Liposomes; Paclitaxel; Xenograft Model Antitumor Assays	2002
Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12 Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; DNA Primers; Docetaxel; Endothelial Growth Factors; fas Receptor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer, 2003, Jan-15, Volume: 97, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome	2003
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Lymph Nodes; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome	2003
[Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Remission Induction; Taxoids	2003
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer, 2003, Mar-15, Volume: 97, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Endpoint Determination; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neutropenia; Paclitaxel; Reproducibility of Results; Survival; Taxoids	2003
Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Blotting, Western; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; HeLa Cells; Humans; In Situ Nick-End Labeling; Kinetics; Mutation; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53	2003
Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status. Cancer science, 2003, Volume: 94, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Hypoxia; Cisplatin; Combined Modality Therapy; DNA Damage; Gamma Rays; Genes, p53; Head and Neck Neoplasms; Humans; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Mice, Nude; Micronucleus Tests; Neoplasm Proteins; Paclitaxel; Radiation-Sensitizing Agents; Tirapazamine; Triazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2003
Dose-intense paclitaxel: deja vu all over again? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel	2003
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. Journal of cellular biochemistry, 2003, Jul-01, Volume: 89, Issue:4 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Division; Cell Line, Transformed; Cyclin-Dependent Kinases; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Head and Neck Neoplasms; Humans; Interleukin-2 Receptor alpha Subunit; Janus Kinase 3; Multienzyme Complexes; Paclitaxel; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin; Tumor Cells, Cultured; Ubiquitin	2003
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Ligands; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Mouth Neoplasms; Neoplasms; Paclitaxel; Phosphorylation; Propidium; Pyrimidines; Pyrroles; Tongue; Tongue Neoplasms; Tyrosine	2003
Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Catechin; Cell Division; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genes, Reporter; Head and Neck Neoplasms; Humans; Immunoblotting; Luciferases; Paclitaxel; Phosphorylation; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Receptor, ErbB-2; Signal Transduction; Time Factors	2003
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate	2003
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncology reports, 2004, Volume: 11, Issue:2 Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Primers; Estrogen Receptor alpha; Fluorouracil; G1 Phase; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Suppressor Protein p53; Vincristine	2004
Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck. Cancer, 2004, Oct-15, Volume: 101, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome	2004
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer, 2004, Nov-15, Volume: 101, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2004
Cutaneous adenocarcinoma metastases associated with swelling of the neck and cheeks. Acta dermato-venereologica, 2004, Volume: 84, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cheek; Head and Neck Neoplasms; Humans; Male; Neck; Neoplasms, Unknown Primary; Paclitaxel; Skin Neoplasms	2004
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer research, 2004, Nov-01, Volume: 64, Issue:21 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Mouth Neoplasms; Paclitaxel; Purines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction	2004
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents, Phytogenic; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Squamous Cell; Carrier Proteins; Caspase 3; Caspase 7; Caspases; Cell Division; Cell Hypoxia; Drug Therapy, Combination; Enzyme Activation; Estradiol; Female; G2 Phase; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transcription Factors; Vascular Endothelial Growth Factor A	2004
Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. International journal of oncology, 2005, Volume: 26, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carboplatin; Carcinoma, Squamous Cell; Cell Proliferation; Enkephalin, Methionine; Head and Neck Neoplasms; Humans; Male; Paclitaxel; Tumor Cells, Cultured	2005
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Squamous Cell; Cell Proliferation; Disease Progression; Enkephalin, Methionine; Head and Neck Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Survival Analysis	2005
Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel. Journal of the European Academy of Dermatology and Venereology : JEADV, 2005, Volume: 19, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Facial Neoplasms; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Paclitaxel; Scalp; Skin Neoplasms	2005
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids	2005
Incidence of mandibular osteoradionecrosis may be low in head and neck cancer patients treated with concurrent radiation and weekly paclitaxel. Medical hypotheses, 2005, Volume: 65, Issue:5 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Comorbidity; Head and Neck Neoplasms; Humans; Incidence; Mandibular Diseases; Osteoradionecrosis; Paclitaxel; Radiation Protection; Risk Assessment; Risk Factors	2005
Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Multivariate Analysis; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2005
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome	2006
Induction redux: once more with taxanes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome	2005
Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2006, Volume: 263, Issue:2 Topics: Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, MDR; Head and Neck Neoplasms; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Paclitaxel; RNA, Neoplasm; Tubulin; Tubulin Modulators	2006
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncology reports, 2006, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Neovascularization, Pathologic; Paclitaxel; Taxoids	2006
Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin. Cancer letters, 2006, Nov-08, Volume: 243, Issue:1 Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Fusaric Acid; Growth Inhibitors; Head and Neck Neoplasms; Humans; Male; Mouth Neoplasms; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Time Factors; Tumor Cells, Cultured	2006
p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck. Oncology reports, 2006, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome	2006
Papuloerythematous rash due to intralymphatic cutaneous metastasis of cancer. Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Head and Neck Neoplasms; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lymphatic Metastasis; Lymphedema; Male; Middle Aged; Paclitaxel; Prednisolone; Respiratory Insufficiency; Skin; Skin Neoplasms; Thyroid Neoplasms	2006
Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Molecular cancer therapeutics, 2006, Volume: 5, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; DNA, Neoplasm; Drug Delivery Systems; Guanine; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Paclitaxel; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2006
Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Anti-cancer drugs, 2006, Volume: 17, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Fluorouracil; Head and Neck Neoplasms; Humans; Malonates; Organoplatinum Compounds; Paclitaxel	2006
Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. American journal of clinical oncology, 2006, Volume: 29, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenoid Cystic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Outcome	2006
Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head & neck, 2007, Volume: 29, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Basal Metabolism; Body Composition; Body Mass Index; C-Reactive Protein; Carboplatin; Carcinoma, Squamous Cell; Cytokines; Female; Head and Neck Neoplasms; Humans; Inflammation; Male; Middle Aged; Motor Activity; Paclitaxel; Radiotherapy, Adjuvant	2007
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncology reports, 2007, Volume: 18, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2007
Palliation of pelvic and head and neck cancer with paclitaxel and a novel radiotherapy regimen. Journal of palliative medicine, 2007, Volume: 10, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; United States	2007
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Head and Neck Neoplasms; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Sirolimus	2008
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging. The Journal of otolaryngology, 2007, Volume: 36, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome	2007
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncology reports, 2008, Volume: 19, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Myeloid Cell Leukemia Sequence 1 Protein; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured	2008
[Effectiveness of taxol in head-neck tumors]. Medizinische Klinik (Munich, Germany : 1983). Supplement, 1993, Volume: 2 Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Survival Rate	1993
The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer letters, 1994, Jun-30, Volume: 81, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids	1994
Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; DNA Damage; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Paclitaxel; Tumor Cells, Cultured; Video Recording	1996
Pharmacodynamics of taxol in human head and neck tumors. Cancer research, 1996, May-01, Volume: 56, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Tumor Cells, Cultured; Tumor Suppressor Protein p53	1996
Paclitaxel: current developmental approaches of the National Cancer Institute. Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 15 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Esophageal Neoplasms; Female; Germinoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; Sarcoma, Kaposi; United States; Urinary Bladder Neoplasms	1995
Factors influencing the drug sensitization of human tumor cells for in situ lipofection. Gene therapy, 1996, Volume: 3, Issue:7 Topics: Animals; Antineoplastic Agents; Bleomycin; Cation Exchange Resins; Chloramphenicol O-Acetyltransferase; Cholesterol; Cisplatin; DNA; Female; Head and Neck Neoplasms; Lipids; Liposomes; Lung Neoplasms; Mechlorethamine; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Phosphatidylethanolamines; Transfection	1996
Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids; Treatment Outcome	1996
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer research, 1996, Nov-15, Volume: 56, Issue:22 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured	1996
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1996, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured	1996
In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. Cancer letters, 1996, Dec-03, Volume: 109, Issue:1-2 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Spheroids, Cellular; Tumor Cells, Cultured	1996
Evaluation of Taxol in head and neck squamous carcinoma multicellular tumor spheroids. Anti-cancer drugs, 1997, Volume: 8, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Cell Line; Head and Neck Neoplasms; Humans; Paclitaxel; Spheroids, Cellular; Tumor Stem Cell Assay	1997
Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured	1997
Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. Archives of otolaryngology--head & neck surgery, 1997, Volume: 123, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Immunohistochemistry; Middle Aged; Mutation; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Tumor Suppressor Protein p53	1997
Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	1997
Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:4 Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Combined Modality Therapy; Disease Models, Animal; Drug Synergism; Female; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Mammary Neoplasms, Animal; Mice; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transduction, Genetic; Treatment Outcome; Tumor Cells, Cultured	1998
Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7). Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:1 Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms	1999
An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. International journal of radiation oncology, biology, physics, 1999, Mar-15, Volume: 43, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Remission Induction; Treatment Failure	1999
Determinants of paclitaxel penetration and accumulation in human solid tumor. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 290, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Culture Techniques; Diffusion; Female; Half-Life; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Mice; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharyngeal Neoplasms; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured	1999
Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids	2000
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. International journal of radiation oncology, biology, physics, 2000, Apr-01, Volume: 47, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Treatment Outcome	2000
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled? Current opinion in oncology, 2000, Volume: 12, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids	2000
The pharmacokinetics of a 1-h paclitaxel infusion. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Uterine Neoplasms	2000
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head & neck, 2000, Volume: 22, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate	2000
Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:2 Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Ceramides; Drug Synergism; G1 Phase; G2 Phase; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Mitosis; Paclitaxel; Resting Phase, Cell Cycle; Tumor Cells, Cultured	2000
[Effect of paclitaxel on cisplatin resistant head and neck squamous multicellular tumor spheroids]. Nihon Jibiinkoka Gakkai kaiho, 2000, Volume: 103, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Death; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Paclitaxel; Tumor Cells, Cultured	2000
In regard to Suntharalingam et al. IJROBP 2000;47(1):49-56. International journal of radiation oncology, biology, physics, 2001, Jan-01, Volume: 49, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Survival Analysis	2001
Docetaxel and cisplatin in head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diuretics; Docetaxel; Head and Neck Neoplasms; Humans; Kidney Tubules; Magnesium; Magnesium Deficiency; Paclitaxel; Taxoids	2000
Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ). International journal of cancer, 2001, Mar-15, Volume: 91, Issue:6 Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2001
A preclinical model for experimental chemotherapy of human head and neck cancer. International journal of oncology, 2001, Volume: 18, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids	2001
Highlights of the Eighth European Cancer Conference. Journal of the International Association of Physicians in AIDS Care, 1995, Volume: 1, Issue:11 Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine	1995
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. Farmaco (Societa chimica italiana : 1989), 2001, Volume: 56, Issue:9 Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Taxoids	2001
Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Archives of otolaryngology--head & neck surgery, 2002, Volume: 128, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Flow Cytometry; Head and Neck Neoplasms; Humans; In Vitro Techniques; Paclitaxel; Signal Transduction; Tumor Cells, Cultured	2002
Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure	2002
Clinical trials referral resource. Clinical trials with taxol. Oncology (Williston Park, N.Y.), 1992, Volume: 6, Issue:3 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel	1992